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Abstract 
 
SEMI-INTERPENETRATING NANOFIBER SCAFFOLDS FOR TRANSBUCCAL MUCOSA 
DRUG DELIVERY 
 
By Donald Chukwuemeka Aduba, Jr., M.S. 
 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Biomedical Engineering at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
 
Research Director: Dr. Hu Yang 
Qimonda Associate Professor, Biomedical Engineering 
 
The oral buccal mucosa is a promising absorption site for drug administration because it 
is permeable, highly vascularized and allows ease of administration. Although there are many 
platforms that have been used for drug delivery, nanofiber scaffolds as a platform for local or 
systemic drug delivery through the oral mucosa have not been fully explored. In this thesis, we 
fabricated a biocompatible electrospun gelatin nanofiber scaffold for local drug delivery at the 
oral mucosa. To stabilize the electrospun gelatin nanofibers and allow non-invasive 
incorporation of therapeutics into the scaffold, photo-reactive polyethylene-glycol (PEG)-
diacrylate was employed to crosslink the scaffold to form semi-interpenetrating networks 
(sIPNs). The crosslinking parameters including concentration of PEG-diacrylate, amount of 
photoinitiator, and crosslinking incubation time of the scaffold were systematically investigated. 
The resulting scaffolds were characterized in terms of their morphology, tensile properties, 
porosity, swelling and degradation. The results confirmed that gelatin electrospun nanofiber 
scaffolds after being photo-crosslinked with PEG-diacrylate retain fiber morphology and show 
improved structural stability and mechanical properties. The mucoadhesiveness of the sIPN 
nanofiber scaffold was confirmed. Nystatin, a drug to treat fungal infections such as candidiasis 
was loaded to the sIPN nanofiber scaffold. Its release kinetics was also studied. 
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CHAPTER 1: INTRODUCTION 
 
 
Oral candidiasis has become a growing affliction within the oral cavity primarily due to the 
human immunodeficiency virus (HIV). Oral candidiasis manifests itself in fungal infections of 
the oral cavity due to poor dental hygiene or within the denture wearing elderly patients. At its 
inception, candidiasis is a common pathological symptom that stems from the infection of any of 
the Candida species such as Candida albicans.
1,2
 From a clinical perspective, oral candidiasis is a 
source of oral discomfort, pain, bad taste sensation and loss of appetite. Candidiasis, commonly 
called oral thrush, is shown as white clusters of bacteria lining the cheeks, tongue and gum lining 
of the oral mucosa. This infection can spread into the esophagus causing more threatening 
secondary infections.
3
 
There are a variety of antifungal drugs available to treat candidiasis. These drugs are 
commonly administered topically or systemically ranging from amphotericin lozenges and oral 
suspensions to azole-group antimycotics in the form of creams, tablets and capsules.
3,4
 The 
recent exploration of using polymeric biomaterials for treatment of oral candidiasis has led to the 
emergence of many biotherapeutics on the market.  Although nanofiber scaffolds have been 
widely used in the fields of tissue engineering and wound healing, their utility in drug delivery, 
particularly local drug delivery to treat oral diseases, has been limited. In this study we fabricated 
a multidimensional gelatin nanofiber scaffold crosslinked with PEG-diacrylate. The use of 
natural polymers such as gelatin enables the scaffold to have widely tunable mechanical 
properties while ensuring biocompatibility with the surrounding cells and tissues within the oral 
mucosa. This scaffold was used to encapsulate nystatin, an anti-fungal drug for potential local 
treatment of candidiasis. This scaffold also possesses mucoadhesive properties to allow 
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attachment to the oral mucosal tissue and locally deliver nystatin to the regions affected by 
candidiasis. The formulation is designed for time-sensitive degradation to target a large drug 
payload released within six hours to ensure patient compliance.  
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CHAPTER 2: BACKGROUND 
 
2.1 Anatomy and physiology of the oral mucosa 
 
The oral cavity comprises the lips, buccal, tongue, hard palate, soft palate and floor of the 
mouth. The lining of the oral cavity is referred to as the oral mucosa, which consists of the 
buccal, sublingual, gingival, palatal and labial mucosa. The mucosal tissues in the cheeks 
(buccal), the floor of the mouth (sublingual) and the ventral surface of the tongue account for 
approximately 60% of the oral mucosal surface area. In the context of drug delivery, the buccal 
and sublingual tissues are the primary absorption sites because they are more permeable than the 
tissues in the other regions of the mouth.
5
 
 
 
Figure 2.1: Anatomy of the oral cavity. (Adapted from Squier [6]) 
**Request granted to reuse image from Oxford University Press and Copyright Clearance Center 
 
The oral mucosa is composed of three tissue layers. The outermost layer is a stratified 
epithelium. Beneath the epithelium is the lamina propria followed by the submucosa, the inner 
most layer of the oral mucosa.
7
 The degree of keratinization and thickness of the buccal mucosa 
varies within different regions of the oral cavity. These two properties, in turn, influence the 
permeability of solutes across the oral mucosa.  
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Figure 2.2: Anatomy of oral mucosa.   (Adapted from Smart, J.D. [8]) 
**Request granted to reuse image from Elsevier and Copyright Clearance Center 
 
The primary function of the oral epithelium is to protect the underlying tissue.
9
 It is the 
first layer that drugs must pass through. Similar to other epithelia in the body, it has a common 
mitotically active basal cell layer that advances through many differentiating intermediate layers 
to the superficial layers. The epithelium of the buccal mucosa is about 40-50 cell layers thick. 
These epithelial cells increase in size and become flatter as they progress from the basal layers to 
the superficial layers.
10
 The buccal mucosa epithelium takes approximately 5-6 days to turnover 
its cells. The composition is dependent on its location in the oral cavity. In mammals, the 
gingivae and hard palate areas are more likely to be keratinized while the mucosa of the soft 
palate, sublingual (underside of tongue) and buccal regions are non-keratinized.
11 Keratinized 
buccal mucosa epithelia contain neutral (no charge) lipids such as ceramides and acylceramides, 
making it impermeable to water and water soluble drugs. Non-keratinized epithelia do not 
contain ceramides or acylceramides. They contain relatively neutral but polar lipids which are 
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mainly cholesterol sulfate and glucosyl ceramides.
12
 These types of epithelia are more permeable 
to water in comparison to keratinized epithelia.
11
 
2.2 Permeability and environment of oral mucosa 
2.2.1 Permeability of oral mucosa 
 
The oral mucosa is a moderately leaky epithelium between the epidermis and intestinal 
mucosa. Mucosa surface absorption is efficient compared to skin because the mucosa does not 
have the stratum corneum epidermis, a significant permeation barrier of the skin.
5
 The 
permeability of the buccal mucosa is 4-4000 times greater than the skin.
13
 There are significant 
differences in permeability between different regions of the oral cavity because of the 
heterogeneous structures and functions of the oral mucosa. Generally, the permeability of the 
oral mucosa decrease in the order of sublingual, buccal, and palatal.
11  
Table 2.1: Physical characteristics of oral mucosal tissue. 
 
Tissue Structure Permeability Blood Flow  
(ml/min/100g tissue) 
References 
Buccal Non-Keratinized Intermediate 20.3 [14], [16] 
Sublingual Non-Keratinized Poor 12.2 [14], [16] 
Gingival Keratinized Intermediate 19.5 [14], [16] 
Palatal Keratinized Very Good 7.0 [14], [16] 
 
It is believed that the permeability barrier of the oral mucosa is a result of intercellular 
material derived from membrane coating granules (MCGs).
17
 MCGs are formed while cells are 
undergoing differentiation. They form at the apical cell surfaces where they fuse with the plasma 
membrane. After fusion, their contents are discharged into the upper one-third of the epithelium. 
This permeability barrier is at the outermost 200 µm of the superficial layer of the oral mucosa 
epithelium. 
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The permeability of a barrier can be evaluated by utilizing tracers.
18,19
 When applied to 
the outer surface of the epithelium, these tracers penetrate through the outermost two layers of 
cells. On the submucosal surface, the tracers permeate to the surface of the outermost cell layers 
of the epithelium. According to permeability studies, flattened surface cell layers are the main 
barrier to permeation. Iso-diametric cell layers are relatively permeable due to their evenly 
distributed dimensions.
19
 In both keratinized and non-keratinized epithelial layers, permeation 
does not occur where MCGs are adjacent to the superficial plasma membranes of the epithelial 
cells.
19 
The structures of the MCGs in keratinized and non-keratinized epithelia are different.
12 
The MCGs of keratinized epithelium are composed of lamellar lipid stacks, whereas the MCGs 
of non-keratinized epithelium contain non-lamellar lipid stacks. More specifically, the MCGs of 
keratinized epithelia are composed of sphingomyelin, glucosylceramides, ceramides, and other 
non-polar lipids. The MCGs of non-keratinized epithelia are made of cholesterol esters, 
cholesterol, and glycosphingolipids.
12
 
 
Outside of MCGs, the oral mucosa’s basement membrane 
may present resistance to permeation but its outer epithelium is still considered to be a rate 
limiting step to mucosal penetration. This is because the structure of the basement membrane is 
not dense enough to prevent the entry of relatively large molecules such as horseradish 
peroxidase tracers commonly used in permeation studies.
10
 
2.2.2 Environment of oral mucosa 
 
The oral epithelia cells are covered by mucus made of proteins and carbohydrates. Mucus 
has a thickness ranging from 40 µm to 300 µm and a molecular mass that ranges from 0.5 to over 
20 mega daltons.
20,21
  These biochemical complexes can be either free of association with or 
bound to certain regions on the cell surfaces. The matrix of these components plays a role in cell 
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to cell adhesion interactions, acting as a lubricant to allow cells to move relative to one another.
22
 
Mucus also plays a role in bioadhesion of mucoadhesive drug delivery systems.
23
 In the oral 
mucosa, mucus is secreted by major and minor salivary glands as part of saliva.
22,24
 Up to 70% 
of mucin in saliva is produced by the minor salivary glands.
22,24
 At physiological pH of 7.4, the 
mucus network carries a negative charge due to sialic acid and sulfate residues which may play a 
role in mucoadhesion. At physiological pH, mucus can form a strongly cohesive gel structure 
that binds to the epithelial cell surface as a gelatinous layer.
7
 Mucus molecules are able to join 
together to make polymers or form an extended three-dimensional network.
5
  
Another feature of the oral cavity environment is the presence of saliva produced by the 
salivary glands. Saliva is a fluid present in the oral cavity protecting the soft tissues from 
abrasion. It also allows for the continuous mineralization of tooth enamel after eruption and 
helps with remineralization of the enamel in the early stages of tooth decay.
25
 Saliva is an 
aqueous fluid containing 1% organic and inorganic materials. The salivary pH ranges from 5.5 to 
7. At high flow rates, the sodium and bicarbonate concentrations increase, resulting in a spike of 
the salivary pH.  Daily salivary volume ranges from 0.5 to 2 liters, needed to hydrate oral 
mucosal dosage forms.
10
 
2.3 Oral mucosa drug absorption 
2.3.1 Principles of drug absorption via the oral mucosa 
 
The oral mucosa has been scrutinized as an absorption site for drug administration 
because its anatomical properties allow for localized and sustained release of therapeutic over an 
extended period of time. The surface area of the oral mucosa is relatively small compared to the 
gastrointestinal tract and skin. Nonetheless, the oral mucosa is highly vascularized, allowing 
drug to diffuse into the oral mucosa membranes and get into the systemic circulation. Drug 
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administration via the oral mucosa bypasses the gastrointestinal tract and first-pass metabolism 
in the liver.
26
 Because of the ampiphilic properties of the epithelial cell layer, the oral mucosa 
represents a tissue barrier for drug absorption. The ampiphilicity of the epithelial cell layer can 
regulate drug absorption via diffusion, ion transport, endocytosis and electroporation 
mechanisms. The absorption of drug molecules across the cell layer can be affected by size or 
polarity of the drug. Enzymes present at the barrier can cause rapid degradation of peptides and 
proteins, hence limiting their transport across the oral mucosa. Several drug design approaches 
have been developed to circumvent limitations of oral mucosa delivery.
5
 An in-depth 
understanding of the oral mucosa absorption mechanisms is necessary to design effective drug 
delivery vehicles to overcome permeation barriers of the mucosa epithelia. 
2.3.2 Drug absorption mechanisms across the oral mucosa 
 
Drug absorption via the oral mucosa is a passive diffusion process that can be described 
by Fick’s first law,  
           
    
  
  
                                                                      (1) 
  
The diffusion coefficient (D), concentration (C) and thickness (x) of the tissue are 
parameters that influence drug absorption over the oral mucosa’s surface area gradient. Other 
important parameters like surface area, duration of drug delivery and concentration should be 
taken into account as well. The amount of drug absorbed is dependent on several factors: drug 
concentration, vehicle of drug delivery, mucosal contact time, venous pH of the absorption site, 
size of the drug molecule, and relative lipid solubility.
27
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Drugs can permeate through the epithelial membranes of the buccal mucosa via 
transcellular or paracellular routes.  
        
 
 
 
 
 
 
Figure 2.3: Graphical representation of different routes of drug permeation.  
(Adapted from Patel, et al. [28]) 
 
As illustrated in Figure 2.3, paracellular transport is the movement of molecules around 
or between cells while transcellular transport is the movement of molecules through cells. Drug 
molecules can use these two routes of transport simultaneously although one route is preferred 
over the other depending on the physicochemical properties of the molecules. In paracellular 
transport, the spaces between cells and their cell cytoplasm are hydrophilic in nature, inhibiting 
the transport of lipophilic molecules. As for transcellular transport, the cell membrane’s 
lipophilic nature would inhibit hydrophilic solutes to diffuse through the epithelial cell layer of 
the oral mucosa due to the solutes’ low partition coefficient.10 
2.3.3. Enhancers of oral mucosa drug absorption 
 
Penetration enhancers can enhance drug permeation by changing the properties of the 
mucosa including increasing cell membrane fluidity, extracting the structural intercellular or 
intracellular lipids, altering cellular proteins, or altering the mucus structure and rheology.
29,30,31
 
Chemical enhancers could be added to a pharmaceutical formulation alone or in combination to 
increase the permeation without causing damage to the mucosa. Permeation enhancement 
efficiency by enhancers also depends on the physicochemical properties of the drug, the 
Paracellular route Transcellular route 
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administration site and the nature of the formulation. Various chemicals have been explored as 
permeation enhancers. Among these chemicals are chelators, surfactants, bile salts, fatty acids 
and non-surfactants.
5
  Lately, chitosan and its derivatives have been extensively used to enhance 
permeation across either monostratified or pluristratified epithelia. Chitosan also improves 
permeation of large molecular weight hydrophilic molecules across the mucosa.
32
 
Drug absorption at the oral mucosa can also be enhanced by electrophoresis, electro-
osmosis and electroporation. During electrophoresis,  electrical fields applied to the mucosal 
epithelium reduce the density of the lipids in the intercellular domain, enabling drugs to 
penetrate through the layer.
5
 Electrical enhancement for drug permeation is most efficient for 
water soluble, ionized compounds. Electro-osmosis facilitates drug transport by using the 
inherent negative charges possessed in human tissues. These negative charges bind to mobile, 
positive counter ions, forming an electrically charged double layer in the tissue capillaries. When 
an electrical field is applied across the tissue, a net flow of water is generated through the tissue 
in conjunction with the solvated counter ion. In electroporation, high potential (20-100 V) pulses 
are applied across the tissue. The electrorestriction forces create temporary perforations or 
microchannels in the tissue. These channels can serve as a drug transport route and are closed 
within a few minutes without inducing any permanent damages to the tissue.
29,32 
 
2.4 Oral mucosa drug delivery systems 
2.4.1. Factors of successful drug delivery within oral mucosa 
 
Drugs in systemic circulation typically have three distinct profiles (Figure 2.4): i) rapid 
drug release for immediate and quick action, ii) pulsatile release with rapid appearance of drug 
into systemic circulation and subsequent maintenance of drug concentration within therapeutic 
profile or iii) controlled release over an extended period of time.
28
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Figure 2.4: Schematic representation of different types of drug delivery release systems. 
(Adapted from Patel, et al. [28]) 
 
Drug delivery vehicles for the oral mucosa should be non-toxic, non-irritable, and non-
immunogenic. Typically, drug release from a polymeric material takes place either through 
diffusion, polymer degradation or a combination of both. Polymer degradation can be done via 
hydrolysis, enzymes, bulk erosion or surface erosion.
33,34
 To achieve efficient drug transport 
across the oral mucosa, delivery vehicles or dosage forms should be tissue adhesive. The 
adhesiveness should be high enough to allow the formulation to rapidly attach to the mucosal 
surface and maintain a long residence time. Quick adhesion of the system at the target site can be 
achieved through “bioadhesion promoters” that use tethered polymers. Residence time is 
important because long residence time allows more drugs to be released at the target site. The 
bioadhesion of the drug delivery material should be minimally influenced by environmental 
factors such as the pH of the oral mucosa.  
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2.4.2. Oral mucosa dosage forms  
 
The goal of oral mucosal drug delivery is not only to achieve therapeutic effectiveness 
but to enhance the patient’s comfort level during buccal administration. Various oral mucosa 
drug delivery vehicles have been developed as dosage forms including solutions, tablets 
(lyophilized and bioadhesive), chewing gum, solution sprays, laminated systems, patches, 
hydrogels, adhesive films, hollow fibers, microspheres, etc.
14
 It is not uncommon to utilize a 
combination of these dosage forms to maximize clinical efficacy while enhancing patient 
comfort during drug administration. 
Solution forms are designed to coat the mucosa for the treatment of local disorders such 
as motility dysfunction and fungal infections. Sodium alginate suspension is an example of a 
bioadhesive liquid used to prevent reflux and deliver therapeutic agents to treat the damaged 
mucosa.
35,36
 Tablets are in the form of solid lozenges. Examples include nitroglycerin sublingual 
tablets, fentanyl lozenges on a handle and prochlorperazine buccal tablets. They are easy for 
patients to use. The drug within the tablet is released locally to the entire oral mucosa but the 
tablet formulation in the oral mucosa has a short residence time. Saliva carrying the dissolved 
drug from the tablet often flows to the esophagus and gastrointestinal tract, resulting in loss of 
bioavailability of the drug.
5
 
 Chewing gum is a relatively new dosage form for oral mucosa drug delivery. The 
advantages of chewing gum include a better control over drug release and the potential to reduce 
variability in drug release and retention times. However, chewing gum is an open system that 
does not interface with the oral mucosa tissue layer. As a result, chewing gum may not be a 
viable vehicle for localized drug release.
 5
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Adhesive patches have also been developed to avoid some drawbacks of other dosage 
forms. Oral mucosa delivery patches have unique characteristics including rapid onset of drug, 
sustained drug release and rapid decline in the drug concentration once the patch is removed. 
They help maintain an intimate and prolonged contact with the oral mucosa, allowing a longer 
duration for drug absorption. A disadvantage of patches is that they only cover a small mucosal 
area and their adhesive backings have to be removed manually, raising patient compliance 
issues.
5
 
Particulate drug delivery systems such as microparticles and nanoparticles often exhibit 
improved performance.
37
 Size, chemistry and the shape of the nanoparticles can influence 
particle velocity, diffusion and adhesion to the mucus surface in a complex manner. These 
immobilized carriers due to their relatively small size show a prolonged gastrointestinal 
residence time after diffusing into the mucous gel layer such as stomach lining.
38
  
2.5 Applicable drugs used for delivery in oral mucosa 
2.5.1 Clinical treatments in oral mucosa 
 
Drug forms applied to the oral mucosa are generally efficient for local and systemic drug 
delivery. Some commercially available drugs and dosage forms used for the oral mucosa are 
listed in Table 2.2. 
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Table 2.2: Commercially available drugs for oral mucosa. (Modified from Christina, et al. [39]) 
Drug Dosage Form Type of Release Product Name Manufacturer 
Fentanyl citrate Lozenge 
Tablet 
Film 
 
Quick 
Quick 
Quick 
Actiq 
Fentora 
Onsolis 
Cephalon 
Cephalon 
Meda 
Pharmaceutical Inc. 
Buprenorphine HCl Tablet Quick Subutex Reckitt Benckiser 
Buprenorphine 
HCL 
and naloxone HCl 
Tablet Quick Suboxane Reckitt Benckiser 
Proclorperazine Tablet Controlled Buccastem Reckitt Benckiser 
Testosterone Tablet Controlled Striant SR Columbia 
Pharmaceuticals 
Nitroglycerine Tablet 
Spray 
Quick Nitrostat W Lambert-P 
Davis-Pfizer 
Pharmaceuticals 
Glyceryl trinitrate Spray Quick Nitromist NovaDel 
Zolpidem Spray 
Tablet 
Quick 
Quick 
Zolpimist 
Suscard 
Forest Laboratories 
Nicotine Chewing gum 
Lozenge 
Quick Nicotinelle Novartis Consumer 
Health 
Miconazole Tablet Quick Loramyc BioAlliance 
Pharma SA 
Cannabis-derived  Spray Quick Sativex GW 
Pharmaceuticals, 
PLC 
Insulin 
 
 
Spray  Quick Oral-lyn Generex 
Biotechnology 
Nystatin Tablet 
Gel 
Oral Suspension 
Capsule 
Quick 
Quick 
Quick 
Controlled 
Bio-statin 
Mycostatin 
Nystex 
Nilstat 
Geneza 
Pharmaceuticals 
Bristol-Myers 
Squibb 
 Lozenge Quick Mycostatin  
 
Oral mucosal delivery of analgesics has received attention as it is a non-invasive and easy 
way to treat pain. For example, fentanyl citrate can be applied locally to the oral mucosa to exert 
rapid analgesia for acute pain. Other drugs delivered via the oral mucosa include sedatives such 
as midazolam, triazolam and etomidate. They have proven to be clinically effective. 
Cardiovascular drugs such as nitroglycerin, captopril, verapamil and propafenone have also been 
studied for potential delivery across the oral mucosa.
5
 More recent oral mucosa delivery systems 
such as aerosols can accurately deliver drugs such as insulin to the mouth. Aerosol formulation 
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can be quickly absorbed through the buccal mucosal lining and oropharynx regions, providing 
sufficient plasma insulin levels to control glucose in patients with diabetes.
40
 
2.5.2. Vaccine administration via the oral mucosa  
 
Recently, oral mucosa administration of vaccines has been developed to treat infectious 
diseases. Oral mucosal drug administration can be effective for vaccinations because of its good 
patient compliance. It is not threatening to children or adults fearful of needles. It is non-invasive 
and is not prone to needle pricking accidents involving medical staff or the patient. Vaccines 
administered via the oral mucosa can elicit a systemic immune response in addition to a local 
immune response at the oral mucosa.
41
 Vaccines to treat infectious diseases such as oral 
candidiasis have also been developed. 
2.5.3 Nystatin as an antifungal drug used in the oral mucosa 
 
Figure 2.5: Chemical structure of nystatin. 
Nystatin is an effective drug used to treat fungal infections such as oral candidiasis 
(thrush) within the mouth. It consists of a macrocyclic lactone, a hydroxylated tetraene diene 
backbone, and a mycosamine residue shown in Figure 2.5. Nystatin shows therapeutic activity by 
binding to the ergosterol component of the fungal cell membrane. As a result, the transmembrane 
channels expand the intracellular components, leading to fungal cell death.
42
 Nystatin is non-
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toxic across membranes and has no major side effects beyond potential nausea and vomiting. It 
comes in a variety of formulations including creams, tablets, oral rinses, gels and pastilles.
43
 
However, none of these formulations have the capability to interact directly with the oral 
mucosa, leading to a short residence time and low bioavailability for systemic circulation. 
Additionally, the current formulations do not provide target specificity for antifungal drug 
delivery in the oral mucosa, especially in the case of oral rinses. Therefore, the development of a 
mucoadhesive platform for antifungal delivery may help drug delivery within the oral mucosa.  
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Materials 
 
Table 3.1: List of materials 
Material Abbreviation 
Polyethylene (glycol) diacrylate (Mn =575 g/mol) PEGDA 
Porcine Type-A Gelatin 
 
Gelatin 
1,1,1,3,3,3-Hexafluoro-2-propanol HFP 
Ethanol 
 
Ethanol 
De-Ionized Water DI-Water 
Phosphate Buffer Saline PBS 
2,2 dimethoxy-2-phenylacetophenone 
 
Dulbecco’s Modified Eagle Medium 
 
Monopotassium Phosphate 
DMPA 
 
DMEM 
 
KH2PO4 
  
Sodium Chloride NaCl 
 
Calcium Chloride 
 
Bio-rad Protein Assay Dye Reagent Concentrate 
 
Mucin (Gastric) 
 
 
CaCl2 
 
Bio-Rad 
 
Mucin 
Sodium Hydroxide NaOH 
 
Nystatin 
 
Nys 
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3.2 Equipment 
 
Table 3.2: List of equipment 
Name Purpose 
MTS Bionix 200 ® Mechanical Testing System Measure mechanical properties of electrospun scaffolds 
Zeiss EVO 50 XVP Scanning Electron Microscope Obtain high resolution images of nanofibers for 
morphology characterization and fiber diameter 
measurement using ImageTool
TM
 
Eppendorf Centrifuge Model: 5415D For Centrifuging materials to be separated into pellet 
and supernatant phases 
UVP Blak-Ray Long Wave UV Lamp 100 W high-
pressure mercury vapor filled lamp 
UV radiation light source for crosslinking samples 
Weighing Balance Used to measure mass of materials needed 
Flexi-Dry FTS System Freeze dry system to dry frozen samples 
Ultra Violet – Visible (UV-Vis) Spectrophotometer Quantitative tool using light absorption to measure the 
amount of sample released 
10 mL Syringe To contain gelatin solutions to be pumped during 
electrospinning 
Spellman CZE100R Power Supply Apply voltage to gelatin solutions for electrospinning 
Shaker Plate 
 
 
Hot Water Bath 
To homogenize and mix polymers and solvents 
 
To provide 37⁰C aqueous environment to simulate drug 
release in physiological conditions in vitro 
  
12000-14000 MW Dialysis Tubing For weight specific elution of drug into filtrate 
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3.3 Experimental methodology 
3.3.1 Preparation of gelatin solutions 
 
The electrospinning solutions were prepared first. Briefly, one gram of gelatin was added 
to 10 mL of HFP. The reaction vial was placed on a shaker plate and shaken continuously for 24 
hours to obtain a homogeneous gelatin/HFP solution.
44,45
 
3.3.2 Preparation of gelatin-nystatin solutions 
 
One gram of nystatin was added to 10 mL of the gelatin/HFP solution. The mixture 
solution was vortexed vigorously to completely dissolve nystatin into a homogenous solution. 
The vial was placed on a shaker plate and shaken continuously for 24 hours.
44,45
 
3.3.3 Electrospinning of nanofibers 
 
To fabricate new fibers, the gelatin solution was drawn up through the blunted needle (18 
G x 1 ½ in) of a 10 ml syringe. The syringe was loaded into a syringe pump, propelling the 
gelatin solution out of the needle 125 mm away from the collecting mandrel at a rate of 5 ml/hr. 
The needle was connected to a positive electrode of a high voltage power supply (Spellman 
CZE100R, Spellman High Voltage Electronics Corporation). The positive electrode contained a 
25 kV voltage that was applied to the needle. This voltage helped the gelatin solution overcome 
the surface tension at the needle tip. These conditions generated a Taylor cone which allowed a 
steady stream of gelatin solution to flow from the needle to the grounded collecting plate in a jet-
like fashion. As the gelatin solution was being streamed from the needle tip, the HFP solvent 
evaporated. Randomly aligned nanofibers were collected on a flat, stainless steel mandrel (7.5 
cm x 2.5 cm x 0.5 cm (L x W x T)) rotating at ~500 rpm. (Figure 3.1)  
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Figure 3.1: Electrospinning apparatus setup.   
Once electrospinning was complete, the gelatin scaffolds were carefully removed from the steel 
mandrel using a razor blade and stored under the degassing shelf.  
3.3.4 Crosslinking of scaffolds 
 
Gelatin is a hydrophilic polymer vulnerable to dissolution in aqueous solutions. 
Crosslinking gelatin is necessary to maintain its mechanical stability. In this study, 1X, 2X, 4X, 
8X crosslinking solutions were made by varying amounts of  PEG-diacrylate (MW = 575 g/mol)   
and DMPA photoinitiator in 2 ml of ethanol (Table 3.3). The crosslinking solution was poured 
on a rectangular nanofiber scaffold (7.5 x 2.5 cm) and allowed to incubate for 30 min.  Next, the 
scaffold from a 14 cm distance was held under UV light (UVP Blak-Ray Long Wave Lamp, 100 
Watts) for 2 minutes on each side of the scaffold. DMPA catalyzed the reaction through its 
decomposition after exposure to UV light. The methylated DMPA segment activated the acrylate 
double bond of the PEG-DA monomer to initiate crosslinking polymerization. The propogation 
of PEG-DA monomers eventually formed a stable network with the gelatin embedded. This 
crosslinking mechanism is shown in Figure 3.2. It involves four steps: decomposition, initiation, 
propagation and termination. 
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Table 3.3: Crosslinker amounts per 2 ml of ethanol. 
Crosslinking 
Amounts  
1X Concentration 2X Concentration 4X Concentration 8X Concentration 
PEG Diacrylate 
Mass 
0.056g/ml 0.112g/ml 0.224g/ml 0.448g/ml 
DMPA Mass 2 mg/ml 4 mg/ml 8 mg/ml 16 mg/ml 
PEG Diacrylate 
Concentration 
5% (v/v) 10% (v/v) 20% (v/v) 40% (v/v) 
DMPA 
Concentration 
0.2% (w/v) 0.4% (w/v) 0.8% (w/v) 1.6% (w/v) 
*all 7.5 x 2.5 cm scaffolds were incubated for 30 minutes before exposure to UV light 
Table 3.4: Different incubation times. 
Incubation Time 30 minutes 12 hours 24 hours 
 30 minutes between 
adding 1X crosslinker 
solution on scaffold and 
exposure to UV light 
12 hours between adding 
1X crosslinker solution on 
scaffold and exposure to 
UV light 
24 hours between adding 
1X crosslinker solution on 
scaffold and exposure to 
UV light 
*all 7.5 x 2.5 cm scaffolds were crosslinked with 2 mL 1X concentration of PEG diacrylate and DMPA 
 
                                        
 
 
Decomposition 
UV Light 
DMPA 
Step 1 
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PEG-Diacrylate 
Monomer 
Step 2 
Methylated DMPA 
segment 
Step 3 
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Figure 3.2: Crosslinking mechanism of PEG-diacrylate. (Modified from [46]) 
3.4 Characterization 
3.4.1 SEM  
 
Prior to SEM imaging, nanofiber scaffolds were placed on a 1 cm diameter stub. The stub 
was placed on a specimen holder and gold sputter coated. SEM images were taken on the Zeiss 
EVO 50 XVP Scanning Electron Microscope. Once the SEM images were compiled, UTHSCSA 
ImageTool
TM software
 was used to measure 60 randomly chosen fibers to determine each diameter 
of fibers within the scaffold. 
3.4.2 Tensile testing 
 
The mechanical properties of nanofiber scaffolds were tested using the MTS Bionix 200 
® Mechanical Testing System in conjunction with TestWorks 4.0 software. The nanofiber 
scaffolds (n = 10) were cut into 20 mm length dog-bone shapes using a punch die                
Termination 
Free radicals 
Cross-Linked Networks  
Step 4 
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(ODC Testing & Molds) with dimensions .75, .125 and .24 inches at its length, narrowest point 
and widest point respectively. The scaffolds mechanical properties including peak load, peak 
stress, modulus, strain at break and energy to break were obtained. 
3.4.3. In vitro degradation studies 
 
The in vitro degradation of scaffolds was evaluated three different media: i) Dulbecco’s 
modified Eagle’s medium (DMEM), (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and simulated saliva fluid (SSF) consisting of KH2PO4, NaCl, CaCl2 and NaOH ions at 37⁰ C.47 
Samples of 1 cm diameter (n=9) from each crosslinked nanofiber scaffold were weighed out and 
then individually immersed in a well filled with 1.5 mL of one of the three solutions. At 6 hr, 12 
hr and 24 hr time-points, samples were taken out and centrifuged for 20 minutes. After 
centrifugation, they were frozen, lyophilized, and weighed. The amount of weight loss due to 
degradation was calculated according to the following formula: 
Weight loss due to degradation (%) =   [(Wo-Wd) /Wo] x 100   (2) 
Where Wo = original weight of the sample, and Wd = weight of the sample after degradation 
3.4.4 Porosity studies 
 
Gelatin nanofiber (1 cm x 1 cm) samples (n=5) were cut out and weighed. Their thickness 
was measured with a digital caliper. The apparent volume (Va) of the scaffold was then 
determined. The volume of the material was determined based on collagen’s density of 1.41 
g/cm
3
.
48
 The porosity in terms of apparent void volume fraction is given below. 
Porosity = [1-(Vg/Va)] x 100            (3) 
Where Vg = mass/material’s density, and Va= 1 cm x 1 cm x thickness 
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3.4.5 Swelling studies 
Nanofiber (1 cm x 1 cm) samples (n=5) were placed in wells filled with 5 mL of pH 7.4 
PBS (one sample per well) at room temperature. They were taken out and immediately blot dried 
at predetermined time points up to 24 hours, weighed, and placed back in the solution. Swelling 
ratio is determined as the ratio of mass of swollen sample at a given time point to the mass of the 
dry sample.  
3.4.6 Mucoadhesion studies  
 
Mucoadhesion of the scaffold was tested by examining attachment of mucin proteins to 
the scaffold. Mucin solution with concentration 1 mg/mL was prepared by weighing out 4 mg of 
mucin dissolved in 1 mL of de-ionized water. The 4 mg/mL solution was then diluted to the 1 
mg/mL concentration by taking a 250 µL aliquot from the 4 mg/mL solution and adding it to 200 
µL of protein assay dye reagent (Bio-rad) and 800 µL of de-ionized water in a 2 mL eppendorf 
tube. The reaction vessel was then vortexed to mix the mucin, DI water and dye reagent 
components. 4X and 8X crosslinked scaffolds (n=8) were immersed in 1 mg/mL mucin solution 
and taken out immediately. The mucin concentration in the remaining solution was assessed by 
Bio-rad assay under the UV-Vis spectrophotometer. PEG only hydrogels, (1 cm diameter, (n=8)) 
were used as a negative control since PEG confers a non-fouling, protein resistant surface. These 
hydrogels were composed of 7.5% (w/v) PEG-1500 and 2% (w/v) DMPA photoinitiator in 2 mL 
of solution containing 1 mL of PEG-DA and water each. In addition, 4X crosslinked gelatin 
hydrogels were used for comparison to evaluate if surface architecture influences mucoadhesion. 
The amount of mucin absorbed onto scaffold was then indirectly determined by the mucin 
concentration change before and after sample immersion. 
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3.4.7 Drug release studies 
 
The 4X nanofiber crosslinked scaffolds were chosen for this study because of its good 
stability in aqueous solutions. These scaffolds containing different amounts of nystatin were 
immersed in PBS (pH 7.4) and loaded into dialysis tubing with molecular weight cutoff at 
(MWCO) 12000-14000 Da. The dosage amounts were varied around the prescribed 100 mg 
Nystatin dosage recommended by the U.S. National Library of Medicine.
49
 These dosages were 
varied to analyze and compare its influence on the drug release profiles, particularly within the 
first six hours. At predetermined time points, a 1 mL of aliquot was withdrawn from the release 
medium for UV-Vis measurement. One mL of fresh PBS, pre-equilibrated at 37⁰C was 
immediately added to maintain its volume. Absorbance of nystatin was measured at 305 nm as 
reported in literature.
42
 The absorbance of the withdrawn solution was measured at each time-
point and referenced against the standard curve to indicate the cumulative amount (mg) of drug 
release shown by the following equation: 
                                               
sampleinNysofamountInitial
ionconcentratLionconcentratL
releasecumulative
aliquotcumulative ][01.0][2.0
%

         (4) 
                               
The loading amount of nystatin was determined as follows. First, a 10 mm diameter 
scaffold was immersed in 10 mL of PBS for over 24 hours to allow complete release of the drug. 
Next, 100 µL of the dissolved nystatin solution was extracted and added with 900 µL of PBS 
(pH 7.4) to dilute the sample for measurement preparation. Lastly, the sample’s nystatin 
absorbance was measured then referenced against the standard curve (Appendix A.3) to find the 
corresponding concentration. The absorbance and concentration was found to be 1.316 and .235 
mg/mL respectively .The concentration was multiplied by a factor of 100 to account for 
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extracting 1 mL of sample from 10 mL of solution and diluting it by another factor of 10. The 
total mass of nystatin eluted from a 10 mm diameter (78.54 mm
2 
area) nanofiber scaffold in 10 
mL of solution was 23.5 mg. The initial amounts of nystatin were set at 50, 100, 200 and 400 mg 
dosages through creating drug loaded nanofiber scaffolds with corresponding areas (167 mm
2
, 
334 mm
2
, 668 mm
2
, 1336 mm
2)
. 
3.4.8 Statistical analysis 
 
Statistical analysis was evaluated on mean scaffold fiber diameters, tensile property 
values, degradation, porosity, swelling mucoadhesion and drug release kinetics. All statistical 
analysis was done using one-factor analysis of variance (ANOVA) and Tukey’s test for 
significance using SigmaPlot 12. P-values less than 0.05 were considered statistically significant. 
Graphical representations of mean data were constructed with Microsoft Excel 2007 with error-
bars representing standard deviations. Statistical analysis data is provided in Appendix B.  
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CHAPTER 4: RESULTS AND DISCUSSION 
4.1 Effects of incubation time of crosslinker 
4.1.1 Effect on morphology  
 
In the crosslinking step, the concentration of PEG-DA and DMPA photoinitiator was 
kept constant at 1X while incubation time of nanofiber scaffolds with crosslinking solution was 
varied. The morphology of the noncrosslinked and crosslinked gelatin nanofiber scaffolds was 
examined by SEM. The untreated scaffolds had the greatest fiber diameter. Increasing incubation 
time had a negligible influence on fiber morphology. No discernible differences in fiber 
morphology among crosslinked and non-crosslinked nanofibers were observed. Incubation time 
increase did not affect the nanofiber definition or its porous network.  
  
 
Figure 4.1: SEM image of (A) electrospun gelatin nanofibers with no crosslinking treatment, (B) 
electrospun gelatin nanofiber mats crosslinked with ethanol, (C) electrospun gelatin nanofiber mats 
crosslinked with 1X concentration of PEG-DA & DMPA before 30 minute incubation, (D) before 12 hour 
incubation, (E) before 24 hour incubation. Scaffolds (B-E) after incubation were exposed to UV light 
treatment for two minutes on each side. Bars: 10µm. 
 
 
A B C 
D E 
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Structural stability of crosslinked gelatin nanofiber scaffolds in three types of media was 
also investigated. A set of SEM images of scaffolds having been immersed in DMEM for 24 
hours are presented here. (Figure 4.2) Non-crosslinked and 30 minute-incubated scaffolds were 
not shown due to their complete degradation. The pores are uniformly distributed across the 
matrix. However, these scaffolds lost a nanofiber network and became more porous. 
 
Figure 4.2: SEM images of (A) degraded 12 hour incubation treated crosslinked electrospun gelatin 
nanofiber mats after 24 hours immersion in DMEM, (B) degraded 24 hour incubation treated crosslinked 
electrospun gelatin nanofiber mats after 24 hours immersion in DMEM All scaffolds (A, B) after 
incubation were exposed to UV light treatment for two minutes on each side. Bars: 10µm. 
 
4.1.2 Effect on fiber diameter 
 
Ethanol was used to dissolve crosslinking reagents. Its impact on crosslinked scaffolds 
was studied as well. Incubating uncrosslinked nanofibers in ethanol alone for 30 minutes resulted 
in a decrease in fiber diameter. This was possibly due to nanofiber shrinkage in ethanol. The 
network still maintained a porous structure and fiber morphology. Increasing incubation time to 
24 h in ethanol in the presence of crosslinking reagents further decreased the fiber diameter. 
There was a 28% decrease in fiber diameter when incubation time was increased from 12 to 24 
hours. Significant statistical differences (p<0.05) were shown for uncrosslinked scaffolds tested 
vs. all groups except ethanol. These differences were also shown for 24 hour incubated scaffolds 
tested vs. all groups. 
A B 
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Table 4.1: Fiber diameter as a function of incubation time. 
 
Figure 4.3: Fiber diameter measurements recorded from uncrosslinked and crosslinked electrospun 
gelatin nanofiber mats of varying incubation times with two minutes of UV radiation on each side. All 
crosslinked scaffolds except ethanol control were treated with 1X concentration of PEG-DA & DMPA.  
 
4.1.3 Effect on tensile properties  
 
The data acquired from mechanical testing confirmed ethanol and incubation time of 
crosslinking reagents significantly changed mechanical properties compared to the untreated 
gelatin nanofiber scaffolds. Specifically, increasing the incubation time had an inverse effect on 
the peak stress and modulus. As shown in Table 4.2, the peak stress increased from 1.759 to 
18.36 MPa, showing a ten-fold increase by ethanol alone. The modulus also increased from to 
606.5 MPa. However, peak stress and modulus declined as incubation time was increased 
particularly with crosslinking reagents. Peak stress was 17.48 MPa for incubated samples then 
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decreased to 17.23 and 11.29 MPa at 12 and 24 hour incubated samples respectively. The 30 
minute incubated samples had a modulus of 554.5 MPa. Increasing the incubation time to 12 
hours slightly decreased the modulus to 523.1 MPa while samples incubated for 24 hours had a 
significant drop in modulus to 367.0 MPa. The drop in peak stress and modulus after increasing 
incubation time can be attributed to the hardening effect of PEG-DA, ethanol and photoinitiator 
crosslinking agents on the scaffold. Strain at break shown in Figure 4.5 showed there was an 
increase by 0.0174 mm/mm when ethanol was used compared to uncrosslinked scaffolds. For the 
30 minute incubation treated scaffolds, their strain at break increased further to 0.0460 mm/mm. 
There was no appreciable change in strain at break when the incubation time was extended from 
30 minutes to 12 and 24 hours. A noticeable trend in the scaffold’s peak stress, modulus and 
strain at break did develop when incubation time of crosslinking reagents was increased, while 
the concentration of crosslinking solution was kept constant. After peak stress and modulus 
testing, statistical differences (p<0.05) were shown for uncrosslinked scaffolds evaluated against 
all subgroups except 24 hour incubated samples. The majority of subgroups evaluated for peak 
load shown no significant statistical differences when tested against each other. 
Table 4.2: Tensile properties as a function of incubation time. 
Sample Thickness 
(in) 
Peak Load (N) Peak Stress 
(MPa) 
Modulus (MPa) Strain At Break 
(mm/mm) 
Energy to 
Break (N*mm) 
Untreated 0.00915 ± 
0.00120 
1.062 ± 0.5374 1.759 ± 1.004 94.28 ± 41.41 0.0286 ± 
0.0120 
0.1045 ± 
0.07620 
Ethanol 0.0130 ± 
0.00670 
16.04± 6.791 18.36± 9.266 606.5± 201.9 0.0460± 0.0134 3.199±1.989 
30 minute 
incubation 
0.0200 ± 
0.00270 
22.07 ± 5.416 17.48 ± 4.758 554.5 ± 153.8 0.0580 ± 
0.0180 
5.758 ± 1.842 
12 hour 
incubation 
0.0140 ± 
0.00180 
15.82 ± 3.975 17.23 ± 0.8915 523.1 ± 153.6 0.0590 ± 
0.0200 
4.350 ± 2.127 
24 hour 
incubation 
0.0280 ± 
0.0114 
18.80 ± 6.006 11.29 ± 4.820 367.0 ± 203.7 0.056 ± 0.0181 4.633 ± 2.263 
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Figure 4.4: Peak stress measurements recorded from uncrosslinked and crosslinked electrospun gelatin 
nanofiber mats of varying incubation times with two minutes of UV radiation on each side. All 
crosslinked scaffolds except ethanol control were treated with 1X concentration of PEG-DA & DMPA. 
All treated samples dried after crosslinking treatment. 
 
 
 
Figure 4.5: Strain at break measurements recorded from uncrosslinked and crosslinked electrospun 
gelatin nanofiber mats of varying incubation times with two minutes of UV radiation on each side. All 
crosslinked scaffolds except ethanol control were treated with 1X concentration of PEG-DA & DMPA. 
All treated samples dried after crosslinking treatment. 
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4.1.4 Effect on in vitro degradation 
 
In vitro degradation studies were conducted to evaluate the scaffold’s stability in several 
media conditions at 37⁰C. Uncrosslinked control and 30 minute incubated samples completely 
degraded in six hours. A longer incubation of crosslinking reagents slowed down the degradation 
progress due to a more stabilized crosslinked structure. The matrix allowed water to diffuse 
through the scaffold, breaking up the water soluble gelatin nanofiber network at 37⁰ C. This 
observation was consistent with the swelling data shown in Figure 4.10. The 30 minute-
incubated samples, the control and ethanol uncrosslinked samples exhibited a much higher 
degree of swelling than the 12 hour and 24 hour-incubated samples. Significant statistical 
differences (p<0.05) were shown for 30 minute incubated samples tested against other subgroups 
evaluated in all media.  
Table 4.3: In vitro degradation in DMEM + 10% FBS as a function of incubation time. 
Immersion Time in Media 30 minute incubation 12 hour incubation 24 hour incubation 
6 hours  100%  ± 0.00 77.10%  ± 1.760% 78.29% ± 7.440% 
12 hours 100% ± 0.00 78.22% ± 8.510% 81.05% ± 7.480% 
24 hours 100% ± 0.00 81.94% ± 3.490% 81.65% ± 5.880% 
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Figure 4.6: Degradation rate of crosslinked electrospun gelatin nanofiber mats of varying incubation 
times with two minutes of UV radiation on each side. All crosslinked scaffolds were treated with 1X 
concentration of PEG-DA & DMPA. Scaffold degradation followed after immersion into DMEM + 10% 
fetal bovine serum. Scaffold degradation followed after immersion into DMEM. Degradation is calculated 
as D(%) =  100 x (wo-wd)/wo, where wo and wd are the weight of the nanofibers before and after 
degradation at selected time points. 
 
Table 4.4: In vitro degradation in simulated salivary fluid as a function of incubation time. 
Immersion time in 
media 
30 minute 
incubation 
12 hour incubation 24 hour incubation 
6 hours  100%  ± 0.00 83.48%  ± 3.030% 83.25% ± 5.600% 
12 hours 100% ± 0.00 84.32% ± 6.940% 85.60% ± 6.380% 
24 hours 100% ± 0.00 84.22% ± 3.130% 83.53% ± 0.300% 
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Figure 4.7: Degradation rate of crosslinked electrospun gelatin nanofiber mats of varying incubation 
times with two minutes of UV radiation on each side. All crosslinked scaffolds were treated with 1X 
concentration of PEG-DA & DMPA. Scaffold degradation followed after immersion into simulated 
salivary fluid. Scaffold degradation followed after immersion into DMEM. Degradation is calculated as 
D(%) =  100 x (wo-wd)/wo, where wo and we are the weight of the nanofibers before and after degradation 
at selected time points. 
 
 
Table 4.5: In vitro degradation in DMEM control as a function of incubation time. 
 
Immersion time in 
media 
30 minute 
incubation 
12 hour incubation 24 hour incubation 
6 hours  93.69%  ± 5.720% 83.48%  ± 5.720% 83.25% ± 1.610% 
12 hours 83.40% ± 1.450% 84.32% ± 1.200% 85.60% ± 2.430% 
24 hours 96.80% ± 5.540% 84.22% ± 1.380% 83.53% ± 3.430% 
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Figure 4.8: Degradation rate of crosslinked electrospun gelatin nanofiber mats of varying incubation 
times with two minutes of UV radiation on each side. All crosslinked scaffolds were treated with 1X 
concentration of PEG-DA & DMPA. Scaffold degradation followed after immersion into DMEM. 
Degradation is calculated as: D(%) = 100 x (wo-wd)/wo, where wo and we are the weight of the nanofibers 
before and after degradation at selected time points.  
 
4.1.5 Effect on porosity 
 
Untreated and ethanol treated samples incubated for 30 minutes had an average porosity 
of 82.15 and 84.58%, respectively. The average porosity of scaffolds incubated with crosslinking 
reagents for 12 hours was 37.12 %. However, 24 hour-incubated samples showed a higher 
porosity than the 12 hour samples, presumably due to a possible degradation of the scaffold in 
ethanol. All subgroups tested showed significant statistical differences (p<0.05) with exception 
to 30 minute incubated samples vs. 24 hour incubated samples and ethanol vs. uncrosslinked 
samples. 
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Figure 4.9: Porosity measurements recorded from uncrosslinked and crosslinked electrospun gelatin 
nanofiber mats of varying incubation times with two minutes of UV radiation on each side. All 
crosslinked scaffolds except ethanol control were treated with 1X concentration of PEG-DA & DMPA. 
 
4.1.6 Effect on swelling 
 
Scaffolds incubated for 30 minutes had higher swelling rates than scaffolds incubated for 
12 and 24 hours. However, there was no significant difference in swelling when the incubation 
time was increased from 12 to 24 hours. After 24 hours in PBS, all samples with exception to 
untreated samples sustained a constant absorption profile as the graph reached a plateau after 
roughly 2 hours in PBS. Untreated samples had the highest swelling ratio among all samples 
examined. Significant statistical differences (p<0.05) were shown for uncrosslinked treated 
scaffolds tested against all other subgroups. 
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Figure 4.10: Swelling kinetics of crosslinked electrospun gelatin nanofiber mats of varying incubation 
times with two minutes of UV radiation on each side. All crosslinked scaffolds were treated with 1X 
concentration of PEG-DA & DMPA. Scaffold swelling followed after immersion into PBS at room 
temperature. Swelling is calculated as S(%) = 100 x (mo-me)/mo, where mo and me are the weights of the 
dry and swollen nanofibers respectively at selected time points. 
4.2 Effects of crosslinker concentration  
 
4.2.1 Effect on morphology 
 
The 1X treatment caused the scaffolds to lose its definition due to the fusion of fibers 
within the network caused by the crosslinking solution. However, the nanofiber scaffold’s 
morphology did not fully collapse and its structure was conserved during crosslinking. The 
crosslinked nanofiber scaffolds at the 8X concentration did not deviate much in morphology 
compared to corresponding scaffolds at lower crosslinker concentrations. Fusion of fibers 
confirmed the crosslinking between gelatin, PEG-DA and DMPA without the morphology being 
compromised.  
 Morphology degradation of crosslinked scaffolds in different media was also studied.  
Regardless of crosslinker concentration and medium, gelatin nanofibers completely fused into an 
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undefined mesh after being immersed. The 1X scaffold completely degraded within six hours. 
There were no available samples from that formulation to image under SEM. Figure 4.12 
confirmed the loss of the scaffold’s nanofiber network. One possible postulation is hydrophilic 
gelatin interacts directly with the surrounding solution, allowing water molecules to penetrate the 
porous gelatin network and causing fiber expansion and swelling within the scaffold. The 
enzymes within the cell culture media were another factor to accelerate degradation of gelatin 
nanofibers. 
 
 
 
 
Figure 4.11: SEM image of (A) electrospun gelatin nanofibers with no crosslinking treatment, (B) 
electrospun gelatin nanofiber mats crosslinked with ethanol (C) 1X concentration of PEG-DA & DMPA, 
(D) 2X concentration of PEG-DA & DMPA, (E) 4X concentration of PEG-DA & DMPA, (F) 8X 
concentration of  PEG-DA & DMPA Scaffolds (B-F) after crosslinking reagent exposure were then 
incubated for 30 minutes before UV light treatment for two minutes on each side. Bars: 10µm. 
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Figure 4.12: After 24 hours immersion in DMEM, SEM images of (A) degraded electrospun gelatin 
nanofiber mats crosslinked with 2X concentration of PEG-DA & DMPA, (B) degraded electrospun 
gelatin nanofiber mats crosslinked with 4X concentration of PEG-DA & DMPA, (C) degraded 
electrospun gelatin nanofiber mats crosslinked with 8X concentration of PEG-DA & DMPA. All 
scaffolds (A-C) after crosslinking reagent exposure were then incubated for 30 minutes before UV light 
treatment for two minutes on each side. Untreated and 1X scaffolds not shown due to complete 
degradation. Bars: 10µm. 
 
4.2.2 Effect of fiber diameter  
 
The morphology of crosslinked modulated electrospun gelatin nanofiber scaffolds was 
further scrutinized through fiber diameter examination. Fiber diameter decreased when gelatin 
nanofibers were incubated in ethanol alone or with crosslinker. There was a 24% decrease in 
diameter of ethanol treated scaffolds as compared to uncrosslinked nanofibers. When 1X 
crosslinker was added to ethanol and used to crosslink nanofibers, the mean fiber diameter 
decreased to 2.27 µm. Shown in Table 4.6 and Figure 4.13, 4X crosslinker concentration resulted 
in the lowest fiber diameter. All uncrosslinked and 1X concentrated scaffolds were significantly 
different (p<0.05) when evaluated against other subgroups with the exception of ethanol. 
When crosslinker concentration was increased from 1X to 8X, the fiber diameter slightly 
decreased but the morphology of the crosslinked nanofiber scaffolds was retained. No significant 
morphological differences were observed across crosslinked scaffolds. (Figure 4.11) The 
scaffolds from each individual treatment displayed fiber fusion, confirming crosslinking within 
the network and a well distributed porous structure.  
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Table 4.6: Fiber diameter as a function of crosslinker concentration. 
 
 
Figure 4.13: Fiber diameter measurements recorded from uncrosslinked and crosslinked electrospun 
gelatin nanofiber mats of varying concentrations of PEG-DA & DMPA. All crosslinked scaffolds except 
uncrosslinked control were incubated for 30 minutes before UV light treatment for two minutes on each 
side. All treated samples dried after crosslinking treatment. 
 
4.2.3 Effect on tensile properties 
 
Tensile testing was conducted to evaluate how gelatin nanofiber scaffolds mechanical 
properties were influenced when the crosslinker concentration was adjusted. Thickness, peak 
load, peak stress, modulus, strain at break and energy to break were all higher in ethanol samples 
compared to untreated samples. Crosslinked samples exhibited lower peak stress values from 
17.48 MPa to 6.609 MPa as the concentrations of PEG-DA and DMPA were increased from 1X 
to 8X respectively. Elastic modulus also declined as a function of crosslinker concentration. 1X 
treated samples failed at 554.5 MPa and 8X treated samples failed at 155.5 MPa. 4X and 8X 
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scaffolds exhibited compromised elastic stiffness at mechanical failure. Also, the evaluated 
scaffolds with a higher concentration of crosslinking agents exhibited a lower fiber diameter and 
lower mechanical strength confirmed by previous work by Milleret et al.
50 
8X treated samples 
tested for strain at break exhibited significant statistical differences (p<0.05) when tested against 
all other subgroups. Eleven out of fifteen subgroup comparisons of crosslinker concentration 
tested for modulus showed no statistical differences. Nine out of fifteen subgroups comparisons 
of crosslinker concentration tested for peak load and peak stress also showed no statistical 
differences. 
Table 4.7: Tensile properties as a function of crosslinker concentration. 
Sample 
Thickness 
(in) 
Peak Load 
(N) 
Peak Stress 
(MPa) 
Modulus 
(MPa) 
Strain At 
Break 
(mm/mm) 
Energy to Break 
(N*mm) 
Untreated 0.00915 ± 
0.00120 
1.062 ± 0.5374 1.759 ± 1.004 94.28 ± 41.41 0.0286 ± 
0.0120 
0.1045 ± 0.07620 
Ethanol 0.0130 ± 
0.00670 
16.04± 6.791 18.36± 9.266 606.5± 201.9 0.0460± 
0.0134 
3.199±1.989 
1X 0.0200 ± 
0.00270 
22.07 ± 5.416 17.48 ± 4.758 554.5 ± 153.8 0.0580 ± 
0.0180 
5.758 ± 1.842 
2X 0.0220 ± 
0.0104 
16.61 ± 5.285 12.40 ± 5.126 383.8 ± 196.7 0.0520 ± 
0.0094 
3.775 ± 2.029 
4X 0.0220 ± 
0.0043 
12.44 ± 1.922 8.715 ± 1.440 251.0 ± 53.63 0.0700 ± 
0.0166 
4.242 ± 1.111 
8X 0.0300 ± 
0.0029 
13.50 ± 1.846 6.609 ± 1.080 155.5 ± 30.39 0.0950 ± 
0.0230 
5.941± 1.928 
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Figure 4.14: Peak stress measurements recorded from uncrosslinked and crosslinked electrospun gelatin 
nanofiber mats of varying concentrations of PEG-DA & DMPA. All crosslinked scaffolds except the 
uncrosslinked control were incubated for 30 minutes before UV light treatment for two minutes on each 
side. All treated samples dried after crosslinking treatment. 
 
 
Figure 4.15: Strain at break measurements recorded from uncrosslinked and crosslinked electrospun 
gelatin nanofiber mats of varying concentrations of PEG-DA & DMPA. All crosslinked scaffolds except 
the uncrosslinked control were incubated for 30 minutes before UV light treatment for two minutes on 
each side. All treated samples dried after crosslinking treatment. 
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4.2.4 Effect on in vitro degradation 
 
Degradation was significantly reduced by increasing crosslinker concentration. However, 
crosslinked scaffolds did not degrade appreciably between 6 h and 24 h. Scaffolds whose 
concentrations of PEG-DA and DMPA were doubled from 1X to 2X kept approximately 10% 
more weight over a 24 hour period. 4X crosslinked scaffolds kept 40% more weight than 1X 
samples. At the highest crosslinker concentration, 8X, scaffolds retained the majority of their 
weight, keeping approximately 70% of its weight over 24 hours. This direct relationship between 
crosslinker concentration and the degree of degradation indicated that gelatin nanofibers became 
increasingly stable to hydrolysis as crosslinker concentration was increased. Significant 
statistical differences (p<0.05) were shown for 1X concentrated scaffolds tested against 4X and 
8X crosslinked scaffold subgroups. 
 
Table 4.8: In vitro degradation in DMEM + 10% FBS as a function of crosslinker concentration. 
Weight Loss in 
Sample 
1X Concentration 2X Concentration 4X Concentration 8X Concentration 
6 hours  100%  ± 0.00 89.25%  ± 5.360% 60.27% ± 2.010% 30.63% ± 4.780% 
12 hours 100% ± 0.00 87.98% ± 2.870% 54.66% ± 4.630% 34.59% ± 2.200% 
24 hours 97.14% ± 4.500% 89.74% ± 10.18% 61.25% ± 8.540% 33.41% ± 0.920% 
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 Figure 4.16: Degradation rate of crosslinked electrospun gelatin nanofiber mats with varying 
concentrations of PEG-DA & DMPA. All crosslinked scaffolds were then incubated for 30 minutes 
before UV light treatment for two minutes on each side.  Scaffold degradation followed after immersion 
into DMEM + 10% fetal bovine serum. Degradation is calculated as D(%) =  100 x (wo-wd)/wo, where wo 
and we are the weight of the nanofibers before and after degradation at selected time points. 
 
Table 4.9: In vitro degradation in SSF as a function of crosslinker concentration. 
 
Weight Loss in 
Sample 
1X Concentration 2X Concentration 4X Concentration 8X Concentration 
6 hours  100%  ± 0.00 86.31%  ± 10.88% 82.31% ± 7.700% 56.75% ± 3.350% 
12 hours 100% ± 0.00 88.55% ± 1.320% 77.22% ± 2.340% 58.82% ± 4.560% 
24 hours 100% ± 0.00 69.10% ± 5.480% 79.54% ± 8.760% 61.12% ± 3.440% 
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Figure 4.17: Degradation rate of crosslinked electrospun gelatin nanofiber mats with varying 
concentrations of PEG-DA & DMPA. All crosslinked scaffolds were then incubated for 30 minutes 
before UV light treatment for two minutes on each side.  Scaffold degradation followed after immersion 
into simulated salivary fluid. Degradation is calculated as D(%) =  100 x (wo-wd)/wo, where wo and wd are 
the weight of the nanofibers before and after degradation at selected time points. 
 
 
Table 4.10: In vitro degradation in DMEM control as a function of crosslinker concentration. 
Weight Loss in 
Sample 
1X Concentration 2X Concentration 4X Concentration 8X Concentration 
6 hours  93.69%  ± 5.720% 65.96%  ± 0.750% 41.55% ± 3.330% 16.94% ± 1.190% 
12 hours 83.40% ± 1.450% 68.51% ± 4.430% 43.47% ± 2.050% 26.14% ± 4.390% 
24 hours 96.80% ± 5.540% 65.39% ± 1.890% 45.36% ± 3.950% 24.49% ± 1.390% 
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Figure 4.18: Degradation rate of crosslinked electrospun gelatin nanofiber mats with varying 
concentrations of PEG-DA & DMPA. All crosslinked scaffolds were then incubated for 30 minutes 
before UV light treatment for two minutes on each side.  Scaffold degradation followed after immersion 
into DMEM. Degradation is calculated as D(%) =  100 x (wo-wd)/wo, where wo and wd are the weight of 
the nanofibers before and after degradation at selected time points. 
 
4.2.5 Effect on porosity 
 
The degree of porosity of the crosslinked scaffolds decreased as crosslinker concentration 
increased. The untreated and ethanol controls exhibited average porosities of 82.15% and 
84.58% respectively. Scaffolds crosslinked with 4X concentration of PEG-DA and DMPA had 
the lowest average porosity at 36.98%. Increasing crosslinker concentration reduced the fiber 
diameter size and porosity within the electrospun scaffold.
51
 Additionally, the data confirmed 
that higher concentrations of PEG-DA and DMPA increased crosslinking and fiber 
interconnecting, leading to smaller diameters and lower porosities within the gelatin scaffold. 
There were significant differences (p<0.05) for ethanol and uncrosslinked treated samples tested 
against all subgroups except when they are evaluated versus each other.  
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Figure 4.19: Porosity measurements recorded from uncrosslinked and crosslinked electrospun gelatin 
nanofiber mats with varying concentrations of PEG-DA & DMPA. All crosslinked scaffolds were then 
incubated for 30 minutes with two minutes of UV radiation on each side. 
4.2.6 Effect on swelling kinetics 
 
The lower crosslinked samples possessed elevated swelling rates but at the cost of high 
degradation. On the other hand, gelatin with the 8X concentration of PEG-DA and DMPA 
exhibited a swelling ratio five times lower than that of 1X (Figure 4.20) but was significantly 
more stable from degradation. The degree of swelling among crosslinked samples were varied 
based on the crosslinking agent concentration. Untreated, control and lower concentrated 
crosslinked samples (1X and 2X) exhibited significant burst swelling in the first 30 minutes.  The 
high crosslinked scaffolds possessed a lower degree of burst swelling 30 minutes post-immersion 
in PBS. The lower degrees of swelling in the 4X and 8X samples were due to the presence of a 
denser crosslinked network. Those crosslinked networks were stable and resistant to water 
absorption as indicated in the degradation studies.  Nine out of fifteen subgroups comparisons of 
crosslinker concentration tested for swelling showed no statistical differences. 
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Figure 4.20: Swelling kinetics of crosslinked electrospun gelatin nanofiber mats of varying 
concentrations of PEG-DA & DMPA. All crosslinked scaffolds were then treated for 30 minutes times 
with two minutes of UV radiation on each side. Scaffold swelling followed after immersion into PBS at 
room temperature. Swelling is calculated as S(%) = 100 x (mo-me)/mo, where mo and me are the weights 
of the dry and swollen nanofibers respectively at selected time points. 
 
4.2.7 Comparison of mucoadhesion  
 
Only 4X crosslinked scaffolds showed mucoadhesiveness. The 4X scaffold absorbed 
approximately 0.2 milligrams per square centimeter as shown on Figure 4.21. The absorption 
was attributed to 4X scaffolds possessing more flexible polymer chains that allowed water to 
diffuse into the matrix. The 4X scaffolds also promoted stability that prevented gelatin to 
dissolve and leak out into the surrounding solution. The 8X crosslinked nanofiber scaffold, 4X 
crosslinked hydrogel and 7.5% (w/v) PEG-1500 hydrogel exhibited negative absorption values. 
The 8X nanofiber scaffold contained an inflexible network, and more PEG chains, inhibiting 
diffusion of mucin and presenting a more resistant surface to protein adhesion. The 4X gelatin 
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crosslinked hydrogel control had poor mucoadhesion due to lack of porosity, preventing 
incorporation of mucin into the network. The 4X control hydrogel confirmed the nanofiber 
design may have had a positive effect on mucoadhesion. The 7.5% (w/v) PEG-1500 hydrogel 
had low mucoadhesion due to the non-fouling surface properties of PEG being inhibiting non-
specific protein binding to the hydrogel surface. Significant statistical differences (p<0.05) were 
shown for 4X nanofiber scaffolds tested against other subgroups in the mucoadhesion study. 
 
Figure 4.21: Cross-sectional mucoadhesion of A) 4X PEG-DA & DMPA crosslinked electrospun gelatin 
nanofibers, B) 8X PEG-DA & DMPA crosslinked electrospun gelatin nanofibers, C) 4X PEG-DA & 
DMPA crosslinked gelatin hydrogels, D) 7.5% (w/v) PEG-1500 hydrogels after immediate immersion in 
1 mg/mL mucin solution. 
 
4.2.8 Comparison of drug release kinetics in 4X scaffolds  
 
4X crosslinked scaffolds were used in the drug release study for its good stability in 
aqueous conditions. Linear release kinetics was observed as in the first 24 hours but began to 
plateau out towards 120 hours. Scaffolds loaded with a low payload of nystatin had faster release 
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kinetics over 24 hour and 120 hour time periods. Scaffolds loaded with 50 and 100 mg of 
nystatin released 33.8 and 55.7% of its drug capacity in 24 hours respectively while 200 and 400 
mg dosages released 32.1 and 25.1% of the total drug over 24 hours. The smaller dosages, 50 
and 100 mg had a corresponding release of 57.1 and 74.1% of total drug after 120 hours. On the 
other hand, after 120 hours 43.3% of drug was released from the 200 mg dosage. The lower drug 
payload 4X scaffolds had faster release kinetics over the time interval because the smaller size of 
those scaffolds allowed for easier diffusion and faster degradation in the release medium whose 
volume was held constant. After 120 hours, the 400 mg dosage released only 35% of total drug, 
which was lowest among all the formulations. The release kinetics of the 50 and 100 dosage 
formulations were statistically different (p<0.05) when evaluated against other dosage 
formulation’s release kinetics. 
 
 
Figure 4.22: Cumulative release kinetics of varying amounts of nystatin: A) 50 mg, B) 100 mg, C) 200 
mg and D) 400 mg loaded in electrospun gelatin nanofibers crosslinked with 4X PEG-DA & DMPA. 
Cumulative nystatin release was measured at predetermined timepoints.  
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CHAPTER 5: SUMMARY & FUTURE WORK 
5.1 Summary 
 
Electrospun nanofibers have been actively studied in tissue engineering scaffolding over 
the last decade. They have been explored for clinical applications in wound healing, orthopedics 
and cellular/tissue regeneration. However, nanofiber scaffolds as drug delivery vehicles within 
the oral cavity are relatively new. The effects of incubation time and concentration of PEG-
diacrylate crosslinker on the structure and properties of crosslinked gelatin scaffolds were 
investigated.  Additionally, the scaffold’s mucoadhesive and drug release kinetics properties 
were tuned to ensure proper interfacing between the scaffold and oral mucosa for local and 
sustained nystatin drug delivery against oral candidiasis. The objective of this project was to find 
the most appropriate physical properties of the scaffold for time sensitive oral drug delivery 
within six hours of implantation. This was done by optimizing the crosslinking parameters with 
respect to incubation time and crosslinker concentration. 
In summary, fiber morphology and tensile properties were retained regardless of 
incubation time or crosslinker concentration. Scaffold porosity was reduced as crosslinker 
concentration increased. In vitro degradation and swelling properties were influenced by the 
degree of porosity as well. Scaffolds with higher crosslinking densities of PEG-DA and greater 
incubation times had lower average porosities, inhibiting diffusion of media into the nanofiber 
gelatin matrix. Scaffolds with lower crosslinking densities and incubation time treatments had a 
greater area of pores within flexible nanofiber architectures to allow infusion of surrounding 
media into the matrix. As a result, higher crosslinked and longer incubation treated scaffolds 
possessed lower swelling ratios and in vitro degradation at room and body temperatures 
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respectively. Scaffolds with a lower crosslinking density and incubation time treatments had 
higher swelling ratios and in vitro degradation in the same conditions. The increased temperature 
in the degradation study conditions caused the gelatin nanofibers to liquefy and dissolve due to 
its transition phase from solid to solution at 37⁰C.52,53 As shown in Table 5.1, it appears that the 
30 minute incubated and 1X concentrated scaffolds possessed the best physical properties for 
oral drug delivery. However, its poor stability and lack of resistance to degradation does not 
allow the particular scaffold to deliver a constant drug dosage within six hours due to its relative 
fast dissolution in high temperature aqueous media. The 8X crosslinked scaffolds also possessed 
good physical characteristics also shown in Table 5.1. These scaffolds were not clinically 
feasible due to its high stability in aqueous solutions, causing the material to hang around in the 
patient’s oral cavity beyond the six hour timeframe, leading to compliance and practicality 
issues. Gelatin scaffolds with 4X crosslinking concentrations were chosen for mucoadhesion and 
drug release studies in place of the 2X scaffolds because of its greater relative stability while 
possessing enough amorphous properties to dissolve in aqueous solution within six hours. 
After physical characterization, 4X concentrated scaffolds were evaluated to determine a 
suitable combination of crosslinker concentration and drug dosage that would produce a 
nanofiber scaffold with good mucoadhesion and controlled drug release properties. The 
mucoadhesion and drug release studies showed that 4X crosslinked gelatin nanofiber scaffolds 
containing 50 and 100 mg nystatin dosages have the capability to work as a bioadhesive patch 
for controlled and efficient drug delivery for oral candidiasis treatment. Yet, the drug payload 
within the targeted first six hours needs to be significantly improved from the 25% cumulative 
release shown for 100 mg dosage loaded samples in the nystatin kinetics study. 
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Table 5.1: Summary table 
Properties 30 minute 
Incubation 
12 hours 
Incubation 
24 hours 
Incubation 
1X 
Concentration 
2X 
Concentration 
4X 
Concentration 
8X 
Concentration 
Fiber 
Morphology 
       
Fiber 
Diameter 
       
Tensile 
Properties 
       
Degradation 
Resistance 
NA   NA    
Porosity        
Swelling        
 
5.2 Future work 
 
Stable electrospun nanofiber scaffolds are novel formulations for drug delivery within the 
oral cavity, helping to improve bioavailabity and extend residence time for local sustained drug 
release in oral candidiasis treatment.  To evaluate the efficacy of the nystatin loaded scaffold, in 
vitro anti-microbial tests should be conducted using nystatin loaded scaffolds on cultured fungal 
cell lines.  Biocompatibility and cell viability studies using oral epithelium cells will need to be 
conducted to ensure the formulation not only effectively treats candidiasis but is also safe for 
patients.  More testing and improvements in mucoadhesion, drug release and degradation studies 
are necessary in the future to achieve clinical feasibility. Direct mucoadhesion tests in different 
physiological environments (i.e. pH and flow rate) need to be done to evaluate the adhesion of 
gelatin nanofiber scaffolds onto the oral mucosa. In vitro tests including tensile detachment 
testing, rheology, rotating cylinder or epithelial cell layer models would be applied to give a 
concrete analysis of the scaffold’s bioadhesion capabilities.54 Integrating an adhesive polymer 
backing on the scaffold would also ensure proper adhesion although direction of the drug release 
from the multi-layered scaffold will also have to be regarded. Drug release studies will be further 
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examined using 2X crosslinked scaffolds to determine if crosslinker concentration and dosage 
level have an influence on nystatin release kinetics. This drug release study can help  
determine if the 2X scaffold formulation can achieve targeted degradation and greater dosage 
release within the first six hours. In vitro degradation testing will also need to be done using 
aqueous media that better reflects the salivary conditions within the oral cavity. Introducing 
mucin proteins, electrolytes such as bicarbonate and magnesium and enzymes like amylase, 
lysozymes and matrix metalloproteinases (MMPs) would improve simulating saliva conditions 
within the oral cavity.
55
 Incorporating these salivary components to the existing simulated 
salivary fluid (SSF) formulation will give a much more accurate physical evaluation of how 
crosslinked gelatin nanofibers interact in saliva. Future in vitro degradation, swelling and drug 
release kinetics testing need to be done using nanofiber gelatin scaffolds immersed in improved 
simulated salivary fluid conditions.  
There are still existing limitations for the practicality of this formulation that will need to 
be rectified in future projects. The physiological environment of the oral cavity introduces 
challenges of drug delivery because of the constant flow of saliva diluting and wash out of drug 
dosages below therapeutic levels, shortening its residence time. The relative small area of the 
buccal mucosa also restricts absorption time and dosage size of the drug loaded scaffold.
56 
 
Metalloproteinase enzymes in saliva that function by degrading extracellular matrix materials 
need to be taken into account in designing scaffolds with six hour targeted degradation and drug 
release.  Evaluating the physical properties of the scaffold in diseased and normal physiological 
conditions in the oral mucosa would also help validate the clinical efficacy of this formulation. 
Lastly, improving material processing, crosslinking methods and exploring other therapeutics for 
safe and effective oral mucosa drug delivery will be considered in future studies. 
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Appendix A 
 
 
Figure A.1: Mucin standard curve 
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Figure A.2: Nystatin standard curve 
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Appendix B 
Interpretation of Statistical Analysis 
Analysis of Variance (ANOVA): 
 p < 0.05 indicates that the data is statistically significant 
Tukey’s Pairwise Comparisons: 
 Tukey’s pairwise comparison is performed to determine if two data values is statistically 
different from one another 
 
One Way Analysis of Variance ---Fiber Diameter as a function of incubation time (Figure 4.3)  
 
Data source: Data 1 in Notebook1 
 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 60 0 3.175 1.992 4.332  
Ethanol 60 0 2.540 2.060 2.873  
30 minute incubation (1X) 60 0 2.160 1.725 2.740  
12 hour incubation (1X) 60 0 2.340 1.763 2.768  
24 hour incubation (1X) 60 0 1.500 1.060 2.202  
 
H = 50.584 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
Uncrosslinked vs 24 hour incub 6593.500 9.813 Yes   
Uncrosslinked vs 30 minute inc 3445.000 5.127 Yes   
Uncrosslinked vs 12 hour incub 3051.000 4.541 Yes   
Uncrosslinked vs Ethanol 2143.000 3.189 No   
Ethanol vs 24 hour incub 4450.500 6.623 Yes   
Ethanol vs 30 minute inc 1302.000 1.938 No   
Ethanol vs 12 hour incub 908.000 1.351 Do Not Test   
12 hour incub vs 24 hour incub 3542.500 5.272 Yes   
12 hour incub vs 30 minute inc 394.000 0.586 Do Not Test   
30 minute inc vs 24 hour incub 3148.500 4.686 Yes   
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance—Fiber Diameter as a function of Crosslinker concentration (Figure 4.13)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 60 0 3.175 1.992 4.332  
Ethanol 60 0 2.540 2.060 2.873  
1X Concentration 60 0 2.160 1.725 2.740  
2X Concentration 60 0 1.540 0.925 2.212  
4X Concentration 60 0 1.215 0.823 2.138  
8X Concentration 60 0 2.015 1.385 3.435  
 
H = 78.135 with 5 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
Uncrosslinked vs 4X Concentrat 8545.000 10.600 Yes   
Uncrosslinked vs 2X Concentrat 7242.500 8.985 Yes   
Uncrosslinked vs 8X Concentrat 4156.500 5.156 Yes   
Uncrosslinked vs 1X Concentrat 3434.000 4.260 Yes   
Uncrosslinked vs Ethanol 2098.000 2.603 No   
Ethanol vs 4X Concentration 6447.000 7.998 Yes   
Ethanol vs 2X Concentration 5144.500 6.382 Yes   
Ethanol vs 8X Concentration 2058.500 2.554 No   
Ethanol vs 1X Concentration 1336.000 1.657 Do Not Test   
1X Concentrat vs 4X Concentrat 5111.000 6.340 Yes   
1X Concentrat vs 2X Concentrat 3808.500 4.725 Yes   
1X Concentrat vs 8X Concentrat 722.500 0.896 Do Not Test   
8X Concentrat vs 4X Concentrat 4388.500 5.444 Yes   
8X Concentrat vs 2X Concentrat 3086.000 3.828 No   
2X Concentrat vs 4X Concentrat 1302.500 1.616 No   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Thickness as a function of incubation time (Table 4.2)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 0.00900 0.00850 0.01000  
Ethanol 10 0 0.0130 0.0109 0.0145  
30 minute incubation (1X) 10 0 0.0180 0.0140 0.0266  
12 hour incubation (1X) 10 0 0.0138 0.0124 0.0154  
24 hour incubation (1X) 10 0 0.0292 0.0181 0.0386  
 
H = 30.752 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
24 hour incub vs Uncrosslinked 330.500 7.170 Yes   
24 hour incub vs Ethanol 162.000 3.514 No   
24 hour incub vs 12 hour incub 131.500 2.853 Do Not Test   
24 hour incub vs 30 minute inc 46.000 0.998 Do Not Test   
30 minute inc vs Uncrosslinked 284.500 6.172 Yes   
30 minute inc vs Ethanol 116.000 2.516 Do Not Test   
30 minute inc vs 12 hour incub 85.500 1.855 Do Not Test   
12 hour incub vs Uncrosslinked 199.000 4.317 Yes   
12 hour incub vs Ethanol 30.500 0.662 Do Not Test   
Ethanol vs Uncrosslinked 168.500 3.655 No   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
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vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance—Thickness as a function of Crosslinker concentration (Table 4.7)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.131) 
Equal Variance Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 0.00900 0.00850 0.01000  
Ethanol 10 0 0.0130 0.0109 0.0145  
1X Concentration 10 0 0.0180 0.0140 0.0266  
2X Concentration 10 0 0.0220 0.0125 0.0334  
4X Concentration 10 0 0.0200 0.0174 0.0251  
8X Concentration 10 0 0.0290 0.0278 0.0319  
 
H = 37.965 with 5 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
8X Concentrat vs Uncrosslinked 442.500 8.012 Yes   
8X Concentration vs Ethanol 304.500 5.514 Yes   
8X Concentrat vs 1X Concentrat 177.500 3.214 No   
8X Concentrat vs 2X Concentrat 155.000 2.807 Do Not Test   
8X Concentrat vs 4X Concentrat 141.500 2.562 Do Not Test   
4X Concentrat vs Uncrosslinked 301.000 5.450 Yes   
4X Concentration vs Ethanol 163.000 2.951 No   
4X Concentrat vs 1X Concentrat 36.000 0.652 Do Not Test   
4X Concentrat vs 2X Concentrat 13.500 0.244 Do Not Test   
2X Concentrat vs Uncrosslinked 287.500 5.206 Yes   
2X Concentration vs Ethanol 149.500 2.707 Do Not Test   
2X Concentrat vs 1X Concentrat 22.500 0.407 Do Not Test   
1X Concentrat vs Uncrosslinked 265.000 4.798 Yes   
1X Concentration vs Ethanol 127.000 2.300 Do Not Test   
Ethanol vs Uncrosslinked 138.000 2.499 No   
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Note: The multiple comparisons on ranks do not include an adjustment for ties. 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Peak Load as a function of incubation time (Table 4.2)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.166) 
Equal Variance Test: Failed (P < 0.050) 
 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 0.889 0.537 1.614  
Ethanol 10 0 14.601 11.171 21.648  
30 minute incubation (1X) 10 0 21.970 16.517 27.424  
12 hour incubation (1X) 10 0 15.623 14.462 18.215  
24 hour incubation (1X) 10 0 17.458 14.843 26.029  
 
H = 27.825 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison Diff of Ranks q p<0.05   
30 minute inc vs Uncrosslinked 322.000 6.985 Yes   
30 minute inc vs Ethanol 120.000 2.603 No   
30 minute inc vs 12 hour incub 110.000 2.386 Do Not Test   
30 minute inc vs 24 hour incub 58.000 1.258 Do Not Test   
24 hour incub vs Uncrosslinked 264.000 5.727 Yes   
24 hour incub vs Ethanol 62.000 1.345 Do Not Test   
24 hour incub vs 12 hour incub 52.000 1.128 Do Not Test   
12 hour incub vs Uncrosslinked 212.000 4.599 Yes   
12 hour incub vs Ethanol 10.000 0.217 Do Not Test   
Ethanol vs Uncrosslinked 202.000 4.382 Yes   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Peak Load as a function of Crosslinker concentration (Table 4.7)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 0.889 0.537 1.614  
Ethanol 10 0 14.601 11.171 21.648  
1X Concentration 10 0 21.970 16.517 27.424  
2X Concentration 10 0 15.316 12.929 20.174  
4X Concentration 10 0 12.177 10.554 13.677  
8X Concentration 10 0 14.235 11.511 15.220  
 
H = 36.665 with 5 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
1X Concentrat vs Uncrosslinked 449.000 8.130 Yes   
1X Concentrat vs 4X Concentrat 254.000 4.599 Yes   
1X Concentrat vs 8X Concentrat 206.000 3.730 No   
1X Concentration vs Ethanol 154.000 2.789 Do Not Test   
1X Concentrat vs 2X Concentrat 131.000 2.372 Do Not Test   
2X Concentrat vs Uncrosslinked 318.000 5.758 Yes   
2X Concentrat vs 4X Concentrat 123.000 2.227 No   
2X Concentrat vs 8X Concentrat 75.000 1.358 Do Not Test   
2X Concentration vs Ethanol 23.000 0.416 Do Not Test   
Ethanol vs Uncrosslinked 295.000 5.342 Yes   
Ethanol vs 4X Concentration 100.000 1.811 Do Not Test   
Ethanol vs 8X Concentration 52.000 0.942 Do Not Test   
8X Concentrat vs Uncrosslinked 243.000 4.400 Yes   
8X Concentrat vs 4X Concentrat 48.000 0.869 Do Not Test   
4X Concentrat vs Uncrosslinked 195.000 3.531 No   
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Note: The multiple comparisons on ranks do not include an adjustment for ties. 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Peak Stress as a function of incubation time (Figure 4.4)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 1.459 0.836 2.425  
Ethanol 10 0 17.517 11.653 22.595  
30 minute incubation (1X) 10 0 17.253 13.560 22.368  
12 hour incubation (1X) 10 0 18.327 14.544 20.211  
24 hour incubation (1X) 10 0 10.216 8.272 13.457  
 
H = 29.270 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
12 hour incub vs Uncrosslinked 290.000 6.291 Yes   
12 hour incub vs 24 hour incub 135.000 2.929 No   
12 hour incub vs Ethanol 18.000 0.390 Do Not Test   
12 hour incub vs 30 minute inc 7.000 0.152 Do Not Test   
30 minute inc vs Uncrosslinked 283.000 6.139 Yes   
30 minute inc vs 24 hour incub 128.000 2.777 Do Not Test   
30 minute inc vs Ethanol 11.000 0.239 Do Not Test   
Ethanol vs Uncrosslinked 272.000 5.901 Yes   
Ethanol vs 24 hour incub 117.000 2.538 Do Not Test   
24 hour incub vs Uncrosslinked 155.000 3.362 No   
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
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vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Peak Stress as a function of Crosslinker concentration (Figure 4.14) 
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 1.459 0.836 2.425  
Ethanol 10 0 17.517 11.653 22.595  
1X Concentration 10 0 17.253 13.560 22.368  
2X Concentration 10 0 10.858 9.144 17.506  
4X Concentration 10 0 8.404 7.943 10.223  
8X Concentration 10 0 6.445 5.972 7.486  
 
H = 44.664 with 5 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
1X Concentrat vs Uncrosslinked 422.500 7.650 Yes   
1X Concentrat vs 8X Concentrat 292.500 5.296 Yes   
1X Concentrat vs 4X Concentrat 197.500 3.576 No   
1X Concentrat vs 2X Concentrat 107.000 1.937 Do Not Test   
1X Concentration vs Ethanol 15.500 0.281 Do Not Test   
Ethanol vs Uncrosslinked 407.000 7.370 Yes   
Ethanol vs 8X Concentration 277.000 5.016 Yes   
Ethanol vs 4X Concentration 182.000 3.296 Do Not Test   
Ethanol vs 2X Concentration 91.500 1.657 Do Not Test   
2X Concentrat vs Uncrosslinked 315.500 5.713 Yes   
2X Concentrat vs 8X Concentrat 185.500 3.359 No   
2X Concentrat vs 4X Concentrat 90.500 1.639 Do Not Test   
4X Concentrat vs Uncrosslinked 225.000 4.074 Yes   
4X Concentrat vs 8X Concentrat 95.000 1.720 Do Not Test   
8X Concentrat vs Uncrosslinked 130.000 2.354 No   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Modulus as a function of incubation time (Table 4.2) 
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.191) 
Equal Variance Test: Failed (P < 0.050) 
 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 77.049 67.471 116.602  
Ethanol 10 0 603.821 414.401 743.849  
30 minute incubation (1X) 10 0 569.202 409.878 684.755  
12 hour incubation (1X) 10 0 535.358 415.855 593.311  
24 hour incubation (1X) 10 0 292.010 178.048 527.663  
 
H = 27.950 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
Ethanol vs Uncrosslinked 293.000 6.356 Yes   
Ethanol vs 24 hour incub 134.000 2.907 No   
Ethanol vs 12 hour incub 38.000 0.824 Do Not Test   
Ethanol vs 30 minute inc 15.000 0.325 Do Not Test   
30 minute inc vs Uncrosslinked 278.000 6.031 Yes   
30 minute inc vs 24 hour incub 119.000 2.581 Do Not Test   
30 minute inc vs 12 hour incub 23.000 0.499 Do Not Test   
12 hour incub vs Uncrosslinked 255.000 5.532 Yes   
12 hour incub vs 24 hour incub 96.000 2.083 Do Not Test   
24 hour incub vs Uncrosslinked 159.000 3.449 No   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Modulus as a function of Crosslinker concentration (Table 4.7)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 77.049 67.471 116.602  
Ethanol 10 0 603.821 414.401 743.849  
1X Concentration 10 0 569.202 409.878 684.755  
2X Concentration 10 0 336.157 201.922 569.997  
4X Concentration 10 0 230.159 212.106 294.247  
8X Concentration 10 0 163.246 136.662 179.930  
 
H = 46.305 with 5 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
Ethanol vs Uncrosslinked 416.000 7.533 Yes   
Ethanol vs 8X Concentration 332.000 6.012 Yes   
Ethanol vs 4X Concentration 197.000 3.567 No   
Ethanol vs 2X Concentration 133.000 2.408 Do Not Test   
Ethanol vs 1X Concentration 14.000 0.254 Do Not Test   
1X Concentrat vs Uncrosslinked 402.000 7.279 Yes   
1X Concentrat vs 8X Concentrat 318.000 5.758 Yes   
1X Concentrat vs 4X Concentrat 183.000 3.314 Do Not Test   
1X Concentrat vs 2X Concentrat 119.000 2.155 Do Not Test   
2X Concentrat vs Uncrosslinked 283.000 5.124 Yes   
2X Concentrat vs 8X Concentrat 199.000 3.603 No   
2X Concentrat vs 4X Concentrat 64.000 1.159 Do Not Test   
4X Concentrat vs Uncrosslinked 219.000 3.965 No   
4X Concentrat vs 8X Concentrat 135.000 2.444 Do Not Test   
8X Concentrat vs Uncrosslinked 84.000 1.521 Do Not Test   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
82 
 
One Way Analysis of Variance--Strain at Break as a function of incubation time (Figure 4.5)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.129) 
Equal Variance Test: Passed (P = 0.456) 
 
Group Name  N  Missing Mean Std Dev SEM  
Uncrosslinked 10 0 0.0286 0.0120 0.00380  
Ethanol 10 0 0.0457 0.0134 0.00424  
30 minute incubation (1X) 10 0 0.0580 0.0180 0.00568  
12 hour incubation (1X) 10 0 0.0588 0.0200 0.00632  
24 hour incubation (1X) 10 0 0.0557 0.0181 0.00573  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 0.00648 0.00162 5.897 <0.001  
Residual 45 0.0124 0.000275    
Total 49 0.0189     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there 
is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 0.946 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor:  
Comparison Diff of Means p q P p<0.050  
12 hour incu vs. Uncrosslinke 0.0302 5 5.760 0.002 Yes  
12 hour incu vs. Ethanol 0.0131 5 2.499 0.405 No  
12 hour incu vs. 24 hour incu 0.00310 5 0.591 0.993 Do Not Test  
12 hour incu vs. 30 minute in 0.000800 5 0.153 1.000 Do Not Test  
30 minute in vs. Uncrosslinke 0.0294 5 5.608 0.002 Yes  
30 minute in vs. Ethanol 0.0123 5 2.346 0.469 Do Not Test  
30 minute in vs. 24 hour incu 0.00230 5 0.439 0.998 Do Not Test  
24 hour incu vs. Uncrosslinke 0.0271 5 5.169 0.006 Yes  
24 hour incu vs. Ethanol 0.01000 5 1.907 0.663 Do Not Test  
Ethanol vs. Uncrosslinked 0.0171 5 3.262 0.162 No  
 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means that 
enclose that comparison.  For example, if you had four means sorted in order, and found no difference between 
means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 vs. 2 are 
enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result of Do Not 
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Test should be treated as if there is no significant difference between the means, even though one may appear to 
exist. 
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One Way Analysis of Variance--Strain at Break as a function of Crosslinker concentration  
(Figure 4.15) 
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.307) 
 
Equal Variance Test: Passed (P = 0.170) 
 
Group Name  N  Missing Mean Std Dev SEM  
Uncrosslinked 10 0 0.0286 0.0120 0.00380  
Ethanol 10 0 0.0457 0.0134 0.00424  
1X Concentration 10 0 0.0580 0.0180 0.00568  
2X Concentration 10 0 0.0522 0.00943 0.00298  
4X Concentration 10 0 0.0704 0.0166 0.00525  
8X Concentration 10 0 0.0953 0.0230 0.00727  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 0.0259 0.00519 20.214 <0.001  
Residual 54 0.0139 0.000257    
Total 59 0.0398     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there 
is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor:  
Comparison Diff of Means p q P p<0.050  
8X Concentra vs. Uncrosslinke 0.0667 6 13.167 <0.001 Yes  
8X Concentration vs. Ethanol 0.0496 6 9.792 <0.001 Yes  
8X Concentra vs. 2X Concentra 0.0431 6 8.508 <0.001 Yes  
8X Concentra vs. 1X Concentra 0.0373 6 7.363 <0.001 Yes  
8X Concentra vs. 4X Concentra 0.0249 6 4.916 0.012 Yes  
4X Concentra vs. Uncrosslinke 0.0418 6 8.252 <0.001 Yes  
4X Concentration vs. Ethanol 0.0247 6 4.876 0.013 Yes  
4X Concentra vs. 2X Concentra 0.0182 6 3.593 0.131 No  
4X Concentra vs. 1X Concentra 0.0124 6 2.448 0.518 Do Not Test  
1X Concentra vs. Uncrosslinke 0.0294 6 5.804 0.002 Yes  
1X Concentration vs. Ethanol 0.0123 6 2.428 0.527 No  
1X Concentra vs. 2X Concentra 0.00580 6 1.145 0.965 Do Not Test  
2X Concentra vs. Uncrosslinke 0.0236 6 4.659 0.021 Yes  
2X Concentration vs. Ethanol 0.00650 6 1.283 0.943 Do Not Test  
Ethanol vs. Uncrosslinked 0.0171 6 3.376 0.179 No  
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means that 
enclose that comparison.  For example, if you had four means sorted in order, and found no difference between 
means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 vs. 2 are 
enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result of Do Not 
Test should be treated as if there is no significant difference between the means, even though one may appear to 
exist. 
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One Way Analysis of Variance--Energy to Break as a function of incubation time (Table 4.2)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 0.0710 0.0315 0.176  
Ethanol 10 0 3.033 1.765 4.190  
30 minute incubation time (1X) 10 0 6.035 4.119 7.115  
12 hour incubation time (1X) 10 0 3.869 3.243 5.251  
24 hour incubation time (1X) 10 0 4.444 2.242 6.793  
 
H = 28.368 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
30 minute inc vs Uncrosslinked 321.000 6.963 Yes   
30 minute inc vs Ethanol 142.000 3.080 No   
30 minute inc vs 12 hour incub 81.000 1.757 Do Not Test   
30 minute inc vs 24 hour incub 61.000 1.323 Do Not Test   
24 hour incub vs Uncrosslinked 260.000 5.640 Yes   
24 hour incub vs Ethanol 81.000 1.757 Do Not Test   
24 hour incub vs 12 hour incub 20.000 0.434 Do Not Test   
12 hour incub vs Uncrosslinked 240.000 5.206 Yes   
12 hour incub vs Ethanol 61.000 1.323 Do Not Test   
Ethanol vs Uncrosslinked 179.000 3.883 Yes   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--Energy to Break as a function of Crosslinker concentration (Table 4.7)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.133) 
Equal Variance Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 10 0 0.0710 0.0315 0.176  
Ethanol 10 0 3.033 1.765 4.190  
1X Concentration 10 0 6.035 4.119 7.115  
2X Concentration 10 0 3.056 2.488 5.140  
4X Concentration 10 0 4.282 3.404 5.025  
8X Concentration 10 0 5.614 4.492 7.432  
 
H = 34.428 with 5 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
8X Concentrat vs Uncrosslinked 397.000 7.189 Yes   
8X Concentration vs Ethanol 193.000 3.495 No   
8X Concentrat vs 2X Concentrat 165.000 2.988 Do Not Test   
8X Concentrat vs 4X Concentrat 111.000 2.010 Do Not Test   
8X Concentrat vs 1X Concentrat 16.000 0.290 Do Not Test   
1X Concentrat vs Uncrosslinked 381.000 6.899 Yes   
1X Concentration vs Ethanol 177.000 3.205 Do Not Test   
1X Concentrat vs 2X Concentrat 149.000 2.698 Do Not Test   
1X Concentrat vs 4X Concentrat 95.000 1.720 Do Not Test   
4X Concentrat vs Uncrosslinked 286.000 5.179 Yes   
4X Concentration vs Ethanol 82.000 1.485 Do Not Test   
4X Concentrat vs 2X Concentrat 54.000 0.978 Do Not Test   
2X Concentrat vs Uncrosslinked 232.000 4.201 Yes   
2X Concentration vs Ethanol 28.000 0.507 Do Not Test   
Ethanol vs Uncrosslinked 204.000 3.694 No   
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Note: The multiple comparisons on ranks do not include an adjustment for ties. 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance--In Vitro Degradation DMEM as a function of incubation time (Figure 4.8)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.480) 
Equal Variance Test: Failed (P < 0.050) 
 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
30 minute incubation (1X) 9 0 90.400 83.910 100.000  
12 hour incubation (1X) 9 0 75.810 71.975 81.635  
24 hour incubation (1X) 9 0 84.170 82.930 86.630  
 
H = 15.903 with 2 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
30 minute inc vs 12 hour incub 132.000 5.543 Yes   
30 minute inc vs 24 hour incub 45.000 1.890 No   
24 hour incub vs 12 hour incub 87.000 3.654 Yes   
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
 
 
 
 
 
 
 
 
  
91 
 
One Way Analysis of Variance--In Vitro Degradation DMEM as a function of Crosslinker concentration 
(Figure 4.18) 
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.434) 
Equal Variance Test: Failed (P < 0.050) 
 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
1X Concentration 9 0 90.400 83.910 100.000  
2X Concentration  9 0 66.260 64.340 68.555  
4X Concentration 9 0 42.510 41.435 46.605  
8X Concentration 9 0 23.380 17.305 26.190  
 
H = 32.855 with 3 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
1X Concentrat vs 8X Concentrat 243.000 7.688 Yes   
1X Concentrat vs 4X Concentrat 162.000 5.125 Yes   
1X Concentrat vs 2X Concentrat 81.000 2.563 No   
2X Concentrat vs 8X Concentrat 162.000 5.125 Yes   
2X Concentrat vs 4X Concentrat 81.000 2.563 No   
4X Concentrat vs 8X Concentrat 81.000 2.563 No   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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One Way Analysis of Variance-In Vitro Degradation DMEM + 10% FBS as a function of incubation time 
(Figure 4.6) 
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.067) 
Equal Variance Test: Passed (P = 0.243) 
 
Group Name  N  Missing Mean Std Dev SEM  
30 minute incubation time (1X) 9 0 100.000 0.000 0.000  
12 hour incubation time (1X) 9 0 79.509 5.230 1.743  
24 hour incubation time (1X) 9 0 79.513 6.413 2.138  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 2 2518.767 1259.384 55.166 <0.001  
Residual 24 547.898 22.829    
Total 26 3066.666     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there 
is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor:  
Comparison Diff of Means p q P p<0.050  
30 minute in vs. 12 hour incu 20.491 3 12.866 <0.001 Yes  
30 minute in vs. 24 hour incu 20.487 3 12.863 <0.001 Yes  
24 hour incu vs. 12 hour incu 0.00444 3 0.00279 1.000 No  
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One Way Analysis of Variance-In Vitro Degradation DMEM + 10% FBS as a function of Crosslinker 
concentration (Figure 4.16)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
1X Concentration 9 0 100.000 100.000 100.000  
2X Concentration  9 0 87.120 84.705 92.705  
4X Concentration 9 0 59.810 52.130 62.550  
8X Concentration 9 0 33.330 31.120 34.955  
 
H = 32.846 with 3 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
1X Concentrat vs 8X Concentrat 238.500 7.546 Yes   
1X Concentrat vs 4X Concentrat 157.500 4.983 Yes   
1X Concentrat vs 2X Concentrat 72.000 2.278 No   
2X Concentrat vs 8X Concentrat 166.500 5.268 Yes   
2X Concentrat vs 4X Concentrat 85.500 2.705 No   
4X Concentrat vs 8X Concentrat 81.000 2.563 No   
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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One Way Analysis of Variance--In Vitro Degradation SSF as a function of incubation time        (Figure 4.7) 
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
30 minute incubation time (1X) 9 0 100.000 100.000 100.000  
12 hour incubation time (1X) 9 0 83.750 80.615 86.740  
24 hour incubation time (1X) 9 0 83.740 81.490 86.475  
 
H = 18.018 with 2 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
30 minute inc vs 24 hour incub 122.000 5.124 Yes   
30 minute inc vs 12 hour incub 121.000 5.082 Yes   
12 hour incub vs 24 hour incub 1.000 0.0420 No   
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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One Way Analysis of Variance----In Vitro Degradation SSF as a function of Crosslinker concentration 
(Figure 4.17)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.428) 
Equal Variance Test: Failed (P < 0.050) 
 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
1X Concentration 9 0 100.000 100.000 100.000  
2X Concentration  9 0 87.070 71.145 90.175  
4X Concentration 9 0 79.860 74.470 85.250  
8X Concentration 9 0 60.070 54.880 62.850  
 
H = 30.132 with 3 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
1X Concentrat vs 8X Concentrat 243.000 7.688 Yes   
1X Concentrat vs 4X Concentrat 129.000 4.081 Yes   
1X Concentrat vs 2X Concentrat 114.000 3.607 No   
2X Concentrat vs 8X Concentrat 129.000 4.081 Yes   
2X Concentrat vs 4X Concentrat 15.000 0.475 No   
4X Concentrat vs 8X Concentrat 114.000 3.607 No   
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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One Way Analysis of Variance--Average Porosity as a function of incubation time (Figure 4.9)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.132) 
Equal Variance Test: Passed (P = 0.254) 
 
Group Name  N  Missing Mean Std Dev SEM  
Uncrosslinked 5 0 82.148 4.099 1.833  
Ethanol 5 0 84.578 5.261 2.353  
30 minute incubation (1X) 5 0 67.804 3.677 1.644  
12 hour incubation (1X) 5 0 37.116 6.468 2.893  
24 hour incubation (1X) 5 0 64.118 6.425 2.873  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 4 7201.685 1800.421 63.795 <0.001  
Residual 20 564.436 28.222    
Total 24 7766.121     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there 
is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor:  
Comparison Diff of Means p q P p<0.050  
Ethanol vs. 12 hour incu 47.462 5 19.977 <0.001 Yes  
Ethanol vs. 24 hour incu 20.460 5 8.612 <0.001 Yes  
Ethanol vs. 30 minute in 16.774 5 7.060 <0.001 Yes  
Ethanol vs. Uncrosslinked 2.430 5 1.023 0.949 No  
Uncrosslinke vs. 12 hour incu 45.032 5 18.955 <0.001 Yes  
Uncrosslinke vs. 24 hour incu 18.030 5 7.589 <0.001 Yes  
Uncrosslinke vs. 30 minute in 14.344 5 6.038 0.003 Yes  
30 minute in vs. 12 hour incu 30.688 5 12.917 <0.001 Yes  
30 minute in vs. 24 hour incu 3.686 5 1.551 0.806 No  
24 hour incu vs. 12 hour incu 27.002 5 11.366 <0.001 Yes  
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One Way Analysis of Variance--Average Porosity as a function of Crosslinker concentration (Figure 4.19)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.460) 
Equal Variance Test: Passed (P = 0.276) 
 
Group Name  N  Missing Mean Std Dev SEM  
Uncrosslinked 5 0 82.148 4.099 1.833  
Ethanol 5 0 84.578 5.261 2.353  
1X Concentration 5 0 67.804 3.677 1.644  
2X Concentration 5 0 54.574 6.467 2.892  
4X Concentration 5 0 36.978 10.521 4.705  
8X Concentration 5 0 54.770 8.895 3.978  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 5 8349.268 1669.854 34.593 <0.001  
Residual 24 1158.529 48.272    
Total 29 9507.797     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there 
is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor:  
Comparison Diff of Means p q P p<0.050  
Ethanol vs. 4X Concentration 47.600 6 15.319 <0.001 Yes  
Ethanol vs. 2X Concentration 30.004 6 9.656 <0.001 Yes  
Ethanol vs. 8X Concentration 29.808 6 9.593 <0.001 Yes  
Ethanol vs. 1X Concentration 16.774 6 5.399 0.010 Yes  
Ethanol vs. Uncrosslinked 2.430 6 0.782 0.993 No  
Uncrosslinke vs. 4X Concentra 45.170 6 14.537 <0.001 Yes  
Uncrosslinke vs. 2X Concentra 27.574 6 8.874 <0.001 Yes  
Uncrosslinke vs. 8X Concentra 27.378 6 8.811 <0.001 Yes  
Uncrosslinke vs. 1X Concentra 14.344 6 4.616 0.034 Yes  
1X Concentra vs. 4X Concentra 30.826 6 9.921 <0.001 Yes  
1X Concentra vs. 2X Concentra 13.230 6 4.258 0.060 No  
1X Concentra vs. 8X Concentra 13.034 6 4.195 0.065 Do Not Test  
8X Concentra vs. 4X Concentra 17.792 6 5.726 0.006 Yes  
8X Concentra vs. 2X Concentra 0.196 6 0.0631 1.000 Do Not Test  
2X Concentra vs. 4X Concentra 17.596 6 5.663 0.006 Yes  
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A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means that 
enclose that comparison.  For example, if you had four means sorted in order, and found no difference between 
means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 vs. 2 are 
enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result of Do Not 
Test should be treated as if there is no significant difference between the means, even though one may appear to 
exist. 
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One Way Analysis of Variance--Swelling as a function of incubation time  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source: Data 1 in Notebook1 
 
Group N  Missing  Median    25%      75%     
Uncrosslinked 35 0 662.774 562.774 728.161  
Ethanol 35 0 435.185 357.870 487.500  
30 minute incubation (1X) 35 0 470.023 428.571 518.211  
12 hour incubation (1X) 35 0 220.521 194.005 261.889  
24 hour incubation (1X) 35 0 261.887 201.071 432.619  
 
H = 74.112 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
Uncrosslinked vs 12 hour incub 3314.000 11.057 Yes   
Uncrosslinked vs 24 hour incub 2686.000 8.962 Yes   
Uncrosslinked vs Ethanol 1620.000 5.405 Yes   
Uncrosslinked vs 30 minute inc 1260.000 4.204 Yes   
30 minute inc vs 12 hour incub 2054.000 6.853 Yes   
30 minute inc vs 24 hour incub 1426.000 4.758 Yes   
30 minute inc vs Ethanol 360.000 1.201 No   
Ethanol vs 12 hour incub 1694.000 5.652 Yes   
Ethanol vs 24 hour incub 1066.000 3.557 No   
24 hour incub vs 12 hour incub 628.000 2.095 No   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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One Way Analysis of Variance--Swelling as a function of Crosslinker concentration (Figure 4.20)   
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
Uncrosslinked 35 0 662.774 562.774 728.161  
Ethanol 35 0 435.185 357.870 487.500  
1X Concentration 35 0 470.023 428.571 518.211  
2X Concentration 35 0 384.071 357.227 406.733  
4X Concentration 35 0 201.556 187.568 210.860  
8X Concentration 35 0 123.895 110.773 129.951  
 
H = 103.116 with 5 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
Uncrosslinked vs 8X Concentrat 4476.000 12.451 Yes   
Uncrosslinked vs 4X Concentrat 3576.000 9.947 Yes   
Uncrosslinked vs 2X Concentrat 2469.000 6.868 Yes   
Uncrosslinked vs Ethanol 1619.000 4.504 Yes   
Uncrosslinked vs 1X Concentrat 1216.000 3.383 No   
1X Concentrat vs 8X Concentrat 3260.000 9.068 Yes   
1X Concentrat vs 4X Concentrat 2360.000 6.565 Yes   
1X Concentrat vs 2X Concentrat 1253.000 3.485 No   
1X Concentration vs Ethanol 403.000 1.121 Do Not Test   
Ethanol vs 8X Concentration 2857.000 7.947 Yes   
Ethanol vs 4X Concentration 1957.000 5.444 Yes   
Ethanol vs 2X Concentration 850.000 2.364 Do Not Test   
2X Concentrat vs 8X Concentrat 2007.000 5.583 Yes   
2X Concentrat vs 4X Concentrat 1107.000 3.079 No   
4X Concentrat vs 8X Concentrat 900.000 2.504 No   
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Note: The multiple comparisons on ranks do not include an adjustment for ties. 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between the two rank 
sums that enclose that comparison.  For example, if you had four rank sums sorted in order, and found no significant 
difference between rank sums 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 
vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed rank sums is a procedural rule, 
and a result of Do Not Test should be treated as if there is no significant difference between the rank sums, even 
though one may appear to exist. 
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One Way Analysis of Variance—Mucoadhesion (Figure 4.21)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Passed (P = 0.618) 
Equal Variance Test: Passed (P = 0.157) 
 
Group Name  N  Missing Mean Std Dev SEM  
4X Nanofiber 8 0 0.262 0.0775 0.0274  
8X Nanofiber 8 0 -0.134 0.106 0.0375  
4X Hydrogel 8 0 -0.0790 0.0889 0.0314  
PEG-1500 Hydrogel 8 0 -0.0850 0.0368 0.0130  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 3 0.797 0.266 40.062 <0.001  
Residual 28 0.186 0.00663    
Total 31 0.982     
 
The differences in the mean values among the treatment groups are greater than would be expected by chance; there 
is a statistically significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor:  
Comparison Diff of Means p q P p<0.050  
4X Nanofiber vs. 8X Nanofiber 0.396 4 13.752 <0.001 Yes  
4X Nanofiber vs. PEG-1500 Hyd 0.347 4 12.041 <0.001 Yes  
4X Nanofiber vs. 4X Hydrogel 0.341 4 11.832 <0.001 Yes  
4X Hydrogel vs. 8X Nanofiber 0.0553 4 1.919 0.536 No  
4X Hydrogel vs. PEG-1500 Hyd 0.00600 4 0.208 0.999 Do Not Test  
PEG-1500 Hyd vs. 8X Nanofiber 0.0493 4 1.711 0.626 Do Not Test  
 
 
A result of "Do Not Test" occurs for a comparison when no significant difference is found between two means that 
enclose that comparison.  For example, if you had four means sorted in order, and found no difference between 
means 4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 vs. 2 are 
enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural rule, and a result of Do Not 
Test should be treated as if there is no significant difference between the means, even though one may appear to 
exist. 
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One Way Analysis of Variance--Drug Release Kinetics (Figure 4.22)  
Data source: Data 1 in Notebook1 
Normality Test (Shapiro-Wilk) Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Data source: Data 1 in Notebook1 
Group N  Missing  Median    25%      75%     
50 mg dosage 30 0 0.448 0.256 0.729  
100 mg dosage 30 0 1.135 0.498 1.910  
200 mg dosage 30 0 1.234 0.518 2.146  
400 mg dosage 30 0 1.810 0.753 3.302  
 
H = 31.379 with 3 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be expected by chance; 
there is a statistically significant difference (P = <0.001) 
 
To isolate the group or groups that differ from the others use a multiple comparison procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q p<0.05   
400 mg dosage vs 50 mg dosage 1485.000 7.794 Yes   
400 mg dosage vs 100 mg dosage 783.000 4.110 Yes   
400 mg dosage vs 200 mg dosage 540.000 2.834 No   
200 mg dosage vs 50 mg dosage 945.000 4.960 Yes   
200 mg dosage vs 100 mg dosage 243.000 1.275 No   
100 mg dosage vs 50 mg dosage 702.000 3.685 Yes   
 
 
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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